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In 2017, more than 70,000 people in the United States died due to drug overdoses; 
of that number, approximately 68% involved prescription or illicit opioids (CDC, 2019). 
Presently, insurance companies and physicians require all opioid use disorder (OUD) 
patients to receive counseling during medication treatment for OUD, despite the lack of 
evidence it is necessary for all patients. This requirement restricts access and creates 
hardship for those who may benefit from medication alone. In an effort to inform policy 
and improve quality of treatment, this nonexperimental, correlational study examined the 
relationship between individual counseling status and treatment outcomes in patients 
receiving medication treatment for OUD. Treatment outcome variables (treatment 
utilization, medication use, and opioid use) were extracted from the electronic health 
records of 11,551 adults who received treatment between January 2016 and January 
2018. The impact of individual counseling on outcome variables was examined while 
controlling for confounding variables (gender, age, race, ethnicity, PTSD/trauma, 




treatment were prone to have experienced PTSD/trauma and anxiety, while males were 
more likely to have CJS involvement. Women were more often retained in care and were 
in treatment for longer periods of time than males. In addition, older patients used OUD 
medication more often than younger patients; however, older patients were also more 
prone to use benzodiazepines and alcohol. Multivariate analyses revealed patients with 
increased rates of treatment utilization were more likely to utilize medication treatment 
and demonstrate reduced opioid use. In addition, higher rates of treatment utilization 
were related to reduced opioid use. Patients with more frequent interruptions in OUD 
treatment more often tested positive for opioids. This study revealed very little evidence 
that counseling during OUD treatment had a positive impact on treatment utilization. Yet, 
it found no evidence that counseling while active in treatment had an impact on 
medication utilization or opioid use. Although counseling may have some benefit for 
some patients in OUD treatment, these findings do not support mandating counseling 
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 INTRODUCTION  
Background of the Problem 
The misuse of opioids is a serious public health crisis in the United States and 
around the world. Its impact is both devastating and far-reaching, affecting nearly every 
individual, community, city, and state across the country. In the U.S., an average of 115 
people die each day due to overdoses on opioids (Centers for Disease Control [CDC], 
2017b; National Institute of Drug Abuse [NIDA], 2018a). It is imperative to identify 
effective and accessible treatments, and quickly put them into practice. While many 
treatments are already in use, progress in halting the opioid crisis has been slow. 
Research is needed to determine advantages of current pharmacotherapies and 
psychosocial approaches, treatment combinations, and treatment settings, specifically 
office-based primary care (Kampman & Jarvis, 2015). 
The focus of this research study was to examine the relationship between 
individual counseling status and several treatment outcomes in patients receiving 
medication treatment for opioid use disorder (OUD). The outcome variables examined 
included treatment utilization, medication utilization, opioid use and other substance use. 
This relationship was examined while controlling for important potential confounding 
variables (e.g., gender, age, race, ethnicity, PTSD/trauma, anxiety, and criminal justice 
system (CJS) involvement).  
Opioid Abuse and Opioid-Related Deaths 
Addiction specialists, healthcare providers (HCPs), and opioid treatment 




worldwide. It is estimated that the prevalence of opioid use is .70% (32.4 million) of the 
world population of adults (National Center for Health Statistics, 2015). In 2018, an 
estimated 10.3 million persons aged 12 and older misused opioids. An estimated 9.9 
million misused prescription opioids, and 808, 000 were heroin users (Substance Abuse 
and Mental Health Services Administration [SAMHSA], 2019a). In 2017, more than 
70,000 people died due to drug overdoses, making it a leading cause of death in the 
United States. Of that number, approximately 68% involved prescription or illicit opioids 
(CDC, 2019). To understand  the scope of economic burden of prescription opioid 
overdoses worldwide, Florence, Zhou, Luo, and Xu (2016) examined reports of fatal 
prescription opioid overdoses from the National Survey of Drug Use and Health. They 
found the financial cost due to fatal overdoses and abuse of prescription opioids to be an 
estimated $78.5 billion. One third of this amount was due to increased healthcare and 
substance abuse treatment costs.   
The “Morbidity and Mortality Weekly Report” compiled by the CDC revealed 
that, during 2017, 130 individuals died each day in the U.S. due to opioids (CDC, 2017b). 
Drug overdose deaths from any opioid including heroin, prescription opioids, synthetic 
opioids, and methadone rose from 16,849 in 1999 to 70,237 in 2017. Furthermore, 
Muhuri, Gfroerer, and Davies (2013) found that among new users of heroin, three out of 
four users reported their problem use began with medically prescribed opioids. Given the 
scope and depth of opioid abuse and its consequences, it is essential to have evidence-
based treatment approaches made widely accessible (American Society of Addiction 




The Opioid Epidemic   
The source of widespread opioid abuse in the U.S. is multifaceted. In the 1980s, a 
poor-quality research study was disseminated that proposed several chronic pain 
conditions could be treated with opioids (Portenoy & Foley, 1986). A large 
pharmaceutical company then developed a highly addictive, opioid-based pain 
medication (OxyContin) and funded a large educational campaign targeting physicians, 
which put forth that chronic pain due to a wide range of serious health problems could be 
safely managed with long-term opioid treatment (Kolodny et al., 2015).   
At around the same time, the Joint Commission of the Accreditation of Healthcare 
Organizations (JCAHO) identified a pattern by physicians of inadequately treating pain 
in patients (Berry & Dahl, 2000). The JCAHO actively encouraged physicians to be more 
aggressive in treating pain. Assuming little risk of harm, physicians began prescribing 
opioids at increased rates. This led to widespread access and proliferation of opioids, 
heightening abuse among patients, even for those who took the medication as instructed.  
The result was pervasive opioid abuse and an opioid epidemic.     
Several measures were instituted to address the problem. In 2017, the President’s 
Commission on Combating Addiction and the Opioid Crisis put forth several 
recommendations for limiting access, and increasing funding for prevention, treatment 
and research (President's Commission, 2017). Notably, the report recommended that 
congress and the federal government provide funding to the National Institute of Drug 
Abuse (NIDA), and the National Institute of Mental Health (NIMH) for a review of 
existing research programs, and for additional research on the prevention and treatment 




In addition, the American Society of Addiction Medicine (ASAM), in a recent 
publication of “National Practice Guidelines for Use of Medications in the Treatment of 
Opioid Use Disorder,” identified several research objectives on the application of 
psychosocial treatments (Kampman & Jarvis, 2015, p. 23). Included among these 
objectives are (a) identifying comparative advantages of specific psychosocial treatments; 
(b) determining the effectiveness of psychosocial treatment in combination with specific 
pharmacotherapies; and (c) identifying psychosocial treatments appropriate for addition 
to buprenorphine or naltrexone that can be delivered in primary care settings (Kampman 
& Jarvis, 2015, p. 39).  
Treatments for Opioid Use Disorder 
Treatments available for opioid use disorder (OUD) include pharmacotherapies 
and psychosocial treatments. Medications include methadone (mu agonist) and 
buprenorphine (partial mu agonist), which are used for treatment and withdrawal 
management. Naltrexone (antagonist) is used for relapse prevention, and naloxone 
(antagonist) for treatment of overdose (Kampman & Jarvis, 2015). It is currently 
recommended that psychosocial treatments such as cognitive behavioral therapy and 
coping skills training, community reinforcement approaches, contingency management, 
and motivational interviewing be added to medication treatment (NIDA, 2018a, 2018b). 
Although medications may be used as a stand-alone treatment, some individuals benefit 
from psychosocial treatments that assist with engagement in treatment, abstinence, and 
prevention of relapse (Dugosh et al., 2016). Successful engagement in treatment has been 
shown to reduce illicit drug use, improve brain function, treatment adherence, health, and 




Medication Treatment   
The four medications most commonly used to treat OUD are methadone (MET), 
buprenorphine (BUP), naloxone (NX), and naltrexone (NTX; Fullerton et al., 2014; Lee 
et al., 2018; NIDA, 2017, 2018b SAMHSA, 2018a; Thomas et al., 2014). BUP acts as an 
agonist at the mu opioid receptor and an antagonist at the kappa receptor (SAMHSA, 
2018a). It acts by lowering risk of abuse and physical dependence, has few withdrawal 
symptoms, possesses a ceiling effect at high doses, and has improved safety over opioid 
full agonists (Lutfy & Cowan, 2004). It is often combined with NX, which acts by 
blocking opioid receptors, thereby blocking opiates and reducing the potential for abuse. 
BUP and BUP combined with NX are delivered in office-based settings, substance abuse 
clinics, and treatment centers. BUP is an effective and widely used medication for the 
treatment of OUD.   
Methadone (MET) is a potent synthetic opioid analgesic that is structurally unique 
among other opioid classes. It has properties similar to morphine; however, it is long 
acting. It eliminates withdrawal symptoms and reduces cravings by acting on the same 
brain targets as heroin and morphine (NIDA, 2018a). It has been used successfully to 
treat heroin dependence for over 40 years, although it must be dispensed at approved 
treatment centers (NIDA, 2018a).  
Naltrexone (NTX) is an opioid antagonist that counters the effects of opioids and 
reduces cravings for opioid-based drugs. If opioids are taken during treatment with NTX, 
withdrawal symptoms ensue. Its use has been limited due to poor adherence and 
tolerability, although it has demonstrated effectiveness when combined with psychosocial 




NIDA, 2018a; Preston et al., 1999). The utilization of medications such as MET, BUP, 
NX, and NTX has significantly improved opioid use treatment in recent years. 
Psychosocial Treatments   
While medications are highly effective in treating OUD, the addition of 
psychosocial treatment has demonstrated mixed results (W. Ling, Hillhouse, Ang, 
Jenkins, & Fahey, 2013; Otto et al., 2014; Stein et al., 2015). Psychologically based 
therapies are thought to assist patients by modifying an individual’s thinking and 
behavior patterns in relation to opioid use, improving health-promoting skills, adherence 
to treatment, and relapse prevention (NIDA, 2018c). Approaches include medical 
management, individual, group and family therapy, cognitive behavioral therapy, 
contingency management, and motivational interviewing (Brooner et al., 2007; DeFulio 
et al., 2012; Fiellin et al., 2014; NIDA, 2016). While not considered a psychosocial 
treatment, peer-support is an adjunctive approach that is effective for some individuals 
(Kampman & Jarvis, 2015, p. 38). Treatment approaches can include 12-step programs 
such as Narcotics Anonymous (NA), Self-Management, and Recovery Therapy 
(SMART), among others. Depending on the type of treatment required to meet treatment 
goals, psychosocial treatments are available at hospitals, outpatient clinics, and 
residential settings.   
Significance of the Study 
Extensive research evidence suggests that  medication treatment for OUD is 
highly effective (Dennis et al., 2014; Fiellin et al., 2008, 2014; Gunderson, Hjelmström, 
& Sumner, 2015; W. Ling et al., 2010, 2013; Mattick, Breen, Kimber, & Davoli, 2014; 




insurance companies require patients to attend counseling during OUD treatment despite 
lack of evidence that it is necessary for all patients (Fiellin et al., 2006, 2013; W. Ling et 
al., 2013; Weiss et al., 2011). This requirement restricts access to care and creates 
hardship for those who may benefit from medication treatment alone. Counseling may 
not be necessary for patients who benefit from medication as a standalone treatment. The 
results of the present study will better inform policy, reduce treatment burden for 
patients, and improve the quality of patient care.     
Purpose of the Study 
The focus of this research study was to examine the relationship between 
individual counseling status and outcome variables in patients receiving medication 
treatment for OUD. The outcome variables examined included treatment utilization 
(maintenance visits, random maintenance visits, rescheduled visits, other encounters, care 
interruptions, no-show visits, total time in care, and time since last visit), medication 
utilization, opioid and other substance use, and treatment retention. The impact on 
outcome variables was examined while controlling for important confounding variables 
(e.g., gender, age, race, ethnicity, PTSD/trauma, anxiety, and CJS involvement).  
Aims and Hypotheses 
Aim 1. What is the relationship between treatment utilization, medication utilization, and 
opioid use in a sample of individuals with opioid use disorder receiving medication 
treatment? 
H1a: Patients with a higher rate of random maintenance visit compliance will have 




H1b: Patients with a higher rate of maintenance visit compliance will have increased 
medication utilization.  
H1c: Patients with a lower rate of “no show” visits will have increased medication 
utilization. 
H1d: Patients with longer total time in care will have increased medication utilization.  
H1e: Patients with a lower rate of rescheduled visits will have increased medication 
utilization.  
H1f: Patients with a lower rate of other encounters will have increased medication 
utilization.  
H1g: Patients with a lower rate of care interruptions will have increased medication 
utilization. 
H1h: Patients with less time since the last visit will have increased medication 
utilization.  
H1i: Patients with a higher rate of random maintenance visit compliance will have 
decreased opioid use.  
H1j: Patients with a higher rate of maintenance visit compliance will have decreased 
opioid use.  
H1k: Patients with a lower rate of “no show” visits will have decreased opioid use. 
H1l: Patients with longer total time in care will have decreased opioid use.  
H1m: Patients with a lower rate of rescheduled visits will have decreased opioid use.  
H1n: Patients with a lower rate of other encounters will have decreased opioid use.  
H1o: Patients with a lower rate of care interruptions will have decreased opioid use. 




H1q: Patients with increased medication utilization will have decreased opioid use. 
Aim 2. Determine if medication utilization mediates the relationship between treatment 
utilization and opioid use in patients receiving medication treatment. 
H2a: Medication utilization will mediate the relationship between rate of random 
maintenance visit compliance and opioid use.  
H2b: Medication utilization will mediate the relationship between rate of maintenance 
visit compliance and opioid use.  
H2c: Medication utilization will mediate the relationship between rate of “no show” 
visits and opioid use. 
H2d: Medication utilization will mediate the relationship between total time in care 
and opioid use.  
H2e: Medication utilization will mediate the relationship between rate of rescheduled 
visits and opioid use.  
H2f: Medication utilization will mediate the relationship between rate of other 
encounters and opioid use.  
H2g: Medication utilization will mediate the relationship between rate of care 
interruptions and opioid use. 
H2h: Medication utilization will mediate the relationship between time since the last 
visit and opioid use.  
Aim 3. Examine the impact of current and prior counseling on treatment utilization, 
medication utilization, substance use, and treatment retention.  
H3a: There will be no difference in rate of random maintenance visit compliance 




H3b: There will be no difference in rate of random maintenance visit compliance 
between patients who have previously been in counseling and those who are not. 
H3c: There will be no difference in rate of maintenance visit compliance between 
patients who are currently in counseling and those who are not. 
H3d: There will be no difference in rate of maintenance visit compliance between 
patients who have previously been in counseling and those who are not. 
H3e: There will be no difference in rate of “no show” visits between patients who are 
currently in counseling and those who are not. 
H3f: There will be no difference in rate of “no show” visits between patients who have 
previously been in counseling and those who are not. 
H3g: There will be no difference in total time in care between patients who are 
currently in counseling and those who are not. 
H3h: There will be no difference in total time in care between patients who have 
previously been in counseling and those who are not. 
H3i: There will be no difference in rate of rescheduled visits between patients who are 
currently in counseling and those who are not. 
H3j: There will be no difference in rate of rescheduled visits between patients who 
have previously been in counseling and those who are not. 
H3k: There will be no difference in rate of other encounters between patients who are 
currently in counseling and those who are not. 
H3l: There will be no difference in rate of other encounters between patients who have 




H3m: There will be no difference in rate of care interruptions between patients who 
are currently in counseling and those who are not. 
H3n: There will be no difference in rate of care interruptions between patients who 
have previously been in counseling and those who are not. 
H3o: There will be no difference in time since last visit between patients who are 
currently in counseling and those who are not. 
H3p: There will be no difference in time since last visit between patients who have 
previously been in counseling and those who are not. 
H3q: There will be no difference in medication utilization between patients who are 
currently in counseling and those who are not. 
H3r: There will be no difference in medication utilization between patients who have 
previously been in counseling and those who are not. 
H3s: There will be no difference in opioid use between patients who are currently in 
counseling and those who are not. 
H3t: There will be no difference in opioid use between patients who have previously 
been in counseling and those who are not. 
H3u: There will be no difference in treatment retention between patients who are 
currently in counseling and those who are not. 
H3v: There will be no difference in treatment retention between patients who have 
previously been in counseling and those who are not. 
Aim 4. To examine the comparative effectiveness of type of psychosocial treatment on 
medication utilization, treatment utilization, and opioid use in patients receiving 




H4a: There will be no difference in rate of random maintenance visit compliance 
across different types of psychosocial treatment. 
H4b: There will be no difference in rate of maintenance visit compliance across 
different types of psychosocial treatment. 
H4c: There will be no difference in rate of “no show” visits across different types of 
psychosocial treatment. 
H4d: There will be no difference in total time in care across different types of 
psychosocial treatment. 
H4e: There will be no difference in rate of rescheduled visits across different types of 
psychosocial treatment. 
H4f: There will be no difference in rate of other encounters across different types of 
psychosocial treatment. 
H4g: There will be no difference in rate of care interruption across different types of 
psychosocial treatment. 
H4h: There will be no difference in time since the last visit across different types of 
psychosocial treatment. 
H4i: There will be no difference in medication utilization across different types of 
psychosocial treatment. 
H4j: There will be no difference in opioid use across different types of psychosocial 
treatment. 
Summary 
The rise in OUD and opioid-related deaths is an urgent public health crisis in the 




for OUD and its related health consequences. Little research has been done on the impact 
of psychosocial treatments such as counseling on outcome variables for the treatment of 
OUD. This is especially important given that most providers of medication treatment 
require patients to receive psychosocial treatment despite lack of research demonstrating 
its effectiveness. These study findings further advance our knowledge of effective 






THEORETICAL FRAMEWORK AND REVIEW OF LITERATURE 
This chapter describes the etiology of OUD, the origin, recent history and impact 
of the opioid epidemic, and current treatment approaches from the perspective that OUD 
is a chronic brain disease requiring long-term treatment and management. Additionally, 
the theoretical framework underpinning the study, the Neuman Systems Model, key 
definitions, and a review of the literature are presented.    
Opioid Use Disorder 
 OUD is a chronic and debilitating disease, which when left untreated may result 
in significant health problems, physiological dependence, overdose, and death. Opioids 
are a class of medications available via prescription and in the form of heroin, an illicit 
opioid (NIDA, 2018a). Opioids come in a variety of forms that are similar in chemical 
composition. Opioids interact with opioid receptors in the body, resulting in many 
physiologic changes including the following: (a) depression of breathing due to 
neurochemical effect on the brainstem, (b) heightened sense of pleasure due to the effects  
on the limbic system, and (c) reduced pain reception throughout the body (NIDA, 2018d).  
Opioids are generally safe when used as prescribed; however, they are widely 
misused and abused. Even when taken as directed, physiological dependence may occur, 
thereby increasing the risk of overdose and death (NIDA, 2018b). The complex nature of 
the disorder, reduced access to treatment, combined with a rapidly growing opioid 
epidemic, has created a public health crisis in the United States and around the world 




continues to present barriers to treatment, reducing access, and slowing the development 
of effective treatments.   
 How it is that some individuals are able to avoid the ravages of opioid abuse 
while others are not, has baffled healthcare professionals and addiction specialists. While 
far from clear, the answer very likely lies in the complex nature of an individual’s 
biology, cognition, personality, life experience, and ability to utilize supports. For 
example, evidence exists that persons with mental health problems such as anxiety and 
depression face a higher risk of developing OUD (Barry et al., 2016; Rosic et al., 2017; 
Savant et al., 2013). Additionally, persons with a tendency toward impulsivity find it 
more difficult to resist using the drug (Baldacchino, Balfour, & Matthews, 2015; 
Tolomeo, Gray, Matthews, Steele, & Baldacchino, 2016). Finally, one’s access to the 
drug, developmental stage, and traumatic experiences may place an individual at further 
risk of OUD (Kumar, Stowe, Han, & Mancino, 2016; Stein et al., 2017).  
The results of extensive biological research have shed light on the brain’s role in 
perpetuating opioid abuse. For instance, there is evidence that an individual’s 
neurobiological makeup may set the stage for genetic vulnerability for abusing opioids.  
Genetics also may play a role in one’s physiological response to opioids, and long-term 
abuse of opioids may affect the delicate balance of neurotransmitters in the brain. The 
interaction of environmental and social factors,  as well as a biological predisposition to 
vulnerable brain pathways leading to opioid abuse, may also produce cravings and 
episodes of relapse years after an individual is no longer dependent (Kosten & George, 
2002). Moreover, brain abnormalities that result from chronic use of opioids can lead to 




& George, 2002). Understanding the complex causes and effects of OUD permits 
clinicians and researchers to identify predictors, develop effective treatments, and quickly 
put them into practice in order to improve patient outcomes.  
Significance of the Opioid Epidemic 
 The opioid epidemic has become a major public health problem in the U.S. and 
around the world. Globally, it is estimated that 15 million people suffer from opioid 
dependence and that 69,000 persons die each year from opioid overdose (World Health 
Organization, 2014). In the U.S., drug overdoses have tripled in the last 15 years (Rudd, 
Seth, David, & Scholl, 2016). In 2015 alone, drug overdoses accounted for 52,404 deaths 
in the U.S., and 33,091 (63.1%) were due to opioids. Further, a study by Florence et al. 
(2016) suggests that overdoses of prescription opioids have resulted in an economic 
burden to the U.S. of $78.5 billion.     
Additionally, the degree to which the opioid epidemic has escalated the spread of 
infectious diseases underscores the health consequences of OUD. For example, from 
2004–2014, there was an increased rates of hepatitis C (400% among 18–29 year olds 
and 325% among 30–39 year olds) and hepatitis B (20, 000 new cases in the U.S. among 
persons who inject drugs; CDC, 2017a). The rates of HIV, endocarditis, epidural abscess, 
and other conditions have also increased among persons who inject drugs (Department of 
Health and Human Services, 2017).  
The cause of the most recent opioid epidemic is complex. In part, it arose from 
the common practice of physicians overprescribing the medication. In the 1990s, the 
Joint Commission of the Accreditation of Hospitals admonished physicians and other 




conditions. As a result, physicians began prescribing opioids in abundance, which led to 
increased access and heightened risk for addiction, even among patients who took the 
medication as prescribed. Furthermore, increased availability of opioids in homes placed 
vulnerable persons such as children and adolescents at risk for addiction and opioid-
related deaths.   
While the widespread overuse of opioids has occurred in the past, factors 
converging to create the most recent epidemic began in the 1980s. Around that time a 
low-quality paper with little scientific merit was disseminated proposing that chronic pain 
conditions could be safely managed over many months or even years with opioids 
(Portenoy & Foley, 1986). Within a few years, a large pharmaceutical company had not 
only developed a highly addictive opioid-based pain medication, (OxyContin) but also 
funded a large educational campaign that targeted physicians and proposed that chronic 
pain, due to a variety of medical conditions, could be safely treated with the long-term 
opioid treatment (Kolodny et al., 2015). Around the same time, a recommendation by the 
Joint Commission of the Accreditation of Hospitals suggested that pain was largely 
undertreated by physicians. The commission actively encouraged physicians to be more 
aggressive in treating pain, especially in view of the recent “so-called” evidence 
demonstrating the safety of opioids. Physicians, who had been reluctant to prescribe 
opioids in the past, began prescribing them at an increased rate, all the while believing 
that there was little-to-no risk of harm to patients.   
Theoretical Framework 
Given the complexity of OUD, it is difficult to understand from the perspective of 




necessary in order to grasp the complex nature and progression of OUD. Examining it 
from the viewpoint that it is both a neurobiological illness and a chronic disease requiring 
ongoing management by healthcare providers and clients over long periods provides a 
useful framework on which the present study was based. Additionally, the Neuman 
Systems Model provides a theoretical framework for understanding OUD in the context of 
multiple contributing factors.   
Neurobiology of Opioid Use Disorder 
One may better understand OUD when taking into account the role the brain plays 
in perpetuating the use of opioids. The brain contains many neurons and synapses that 
generate neurotransmitters. Neurotransmitters shape one’s thinking and behavior, respond 
to stimuli, and maintain all vital functions in the body (NIDA, 2016b). In addition, they 
permit neurons to communicate signals to other nearby neurons. In order to maintain 
essential bodily functions, the action of neurotransmitters in the brain must remain in 
balance (Halter, 2014). Many people continue to use opioids due to their effect on the 
“reward” center of the brain. The euphoria one experiences from using opioids is thought 
to be due to stimulation of the reward system with an excess of dopamine (NIDA, 
2016b). Normally, this action mobilizes an individual to continue behaviors needed in 
order to survive, such as eating and experiencing pleasure during contact with loved ones 
(Hazeldon Betty Ford Foundation, 2015). That euphoria experienced after using opioids 
is what prompts individuals to use the drug repeatedly. Eventually, tolerance develops, as 
well as the need to take more and more of the drug to gain that sense of “high.”    
Moreover, the long-term effects of using opioids cause changes in the executive 




al., 2011). Prolonged use of opioids leading to physiologic dependence results in 
compulsive drug-seeking at any cost (Kreek et al., 2012). The results of a study by 
Upadhyay et al. (2010) found that among prescription opioid-dependent subjects, notable 
changes occurred in axonal pathways to the amygdala and functional connectivity to 
amygdala subdivisions. The researchers found that the longer the duration of opioid 
exposure, the greater the changes in functional connectivity of the brain. The findings 
suggest that prolonged opioid exposure is associated with changes in the brain 
responsible for the regulation of affect, control of impulses, and motivation (Upadhyay et 
al., 2010). Furthermore, the extent to which brain function is altered by opioid abuse 
itself, may be due to a genetic predisposition for the development of OUD that 
necessitates long-term treatment and management. 
Opioid Abuse as a Chronic Brain Disease 
 In 2011, the American Society of Addiction Medicine (ASAM) put forth a new 
definition of addiction. The definition resulted from a concerted process involving more 
than 80 experts in the field of addiction from across the United States. The definition 
describes addiction as a primary disease, not the result of behavioral or emotional 
problems. OUD is recognized by the organization as a chronic illness much like diabetes 
or heart disease. It is presently identified as a chronic brain disease with periods of 
relapse and remission that cannot be cured (but rather managed), and should be treated as 
such (ASAM, 2014). 
“Addiction is a primary, chronic disease of brain reward, motivation, memory and 
related circuitry. Dysfunction in these circuits leads to characteristic biological, 
psychological, social and spiritual manifestations. This is reflected in an 
individual pathologically pursuing reward and/or relief by substance use and other 
behaviors. Without treatment or engagement in recovery activities, addiction is 




According to the ASAM (2014), OUD is a chronic brain disease affecting the 
reward system, motivation, memory, and related neurophysiology. Abuse of opioids over 
time leads to disturbances in neurophysiology resulting in distinct behavioral, 
psychological, and social symptoms. In order to gain relief, an individual compulsively 
seeks opioids and engages in behaviors in order to relieve the symptoms. Without 
treatment and recovery, opioid abuse is progressive and may lead to death (ASAM, 
2011b).  
Much like other chronic diseases, OUD presents with periods of relapse and 
remission, and has no cure. As with any chronic illness, treatment is aimed at effectively 
coping with symptoms over time. Managing OUD requires preventative, patient-oriented, 
and individualized continuing care. According to the ASAM (2014), optimal treatment of 
OUD is coordinated and provided in three phases: identification, stabilization, and 
patient-self management. A wide range of treatments are available in a comprehensive 
plan of care, including commonly used medications: MET, BUP or BUP/NX and NTX.  
The medications can be used at all phases of treatment, are highly effective and often 
underutilized (ASAM, 2013). While most chronic diseases require medications for long-
term management, persons requiring medications for OUD, are subject to numerous 
barriers in receiving pharmacological treatment. Barriers include, but are not limited to, 
regulatory and insurance restrictions on prescribing practices, dosage, access, treatment 
duration, a complex system of prior-authorization requirements, and step-therapy 
treatment approaches. In order to provide high-quality evidence-based treatment for 




Proposing that OUD is a chronic disease as opposed to a problem rooted in 
behavior alone has many advantages. First, it explains the compulsive nature of opioid 
abuse despite consequences to the individual, family members, and society. The behavior 
is a manifestation of a disease that involves many parts of the brain. Second, it suggests 
that neurobiology plays a significant role in an individual’s vulnerability and likelihood 
to develop the disease. Furthermore, treatment approaches are now available that target 
the brain itself, as well as the changes that have occurred due to long-term opioid abuse. 
Finally, viewing OUD as a chronic disease such as diabetes or heart disease implies that 
it requires ongoing  management and treatment, perhaps, over a lifetime (ASAM, 2011a).  
The Neuman Systems Model 
 The Neuman Systems Model (NSM) was originally derived from general systems 
theory and is based on the principle that individuals are open systems interacting with one 
another and the environment (Neuman, 1982). Neuman synthesized knowledge from 
several disciplines in order to develop the theory but incorporated many of her own ideas 
from her clinical work in mental health nursing. The model draws a number of ideas from 
Gestalt Theory (Perls, 1973), which defines homeostasis as an important process by 
which an organism maintains its equilibrium and well-being. In order to maintain health, 
an organism must continually adapt to its environment. At any time, the system may 
become stressed, which threatens the balance and stability of the organism; therefore 
adjustment to stressors is a continuous and active process. According to Neuman, in the 
event that the adjustment process fails during an attempt to stabilize an organism during a 





The NSM views an individual as an open/permeable system that is continually 
responding and adapting to stress from the environment. The variables that determine 
successful adaption may be physiological, psychological, sociocultural, developmental, 
and spiritual (Neuman & Fawcett, 2011). Neuman views individuals as possessing a core 
structure that is safeguarded by lines of resistance. An individual’s level of health is 
determined by well-functioning normal lines of defense (NLD; Neuman, 2011). Should 
the NLD become overtaxed, a flexible line of defense (FLD) protects it. Stressors are one 
of three kinds: intra-, inter-, and extrapersonal forces that exist in internal, external, and 
created environments. In the event a stressor becomes too great and overtaxes the FLD, 
the system goes into a state of disequilibrium, thereby becoming unstable (Neuman & 
Fawcett, 2011). As this occurs, lines of resistance are activated, which causes the system 
to move into a state of illness. If the system possesses adequate energy and support, it 
will re-stabilize, and the NLD may be restored either to its original state or improved 
from its previous state (Gonzalo, 2011). 
Concepts Central to the Neuman Systems Model 
The major concepts described are integral to the NSM. They include the 
following: holistic approach, open system, process, feedback, negentropy, stability, 
environment, client system, lines of defense, normal line of defense, flexible line of 
defense, stressor, health, illness, prevention (as intervention at the primary, secondary, 
and tertiary levels) and reconstitution (Alligood, 2014; Marriner-Tomey & Alligood, 




Holistic Approach   
NSM is a dynamic, open, systems approach to nursing care of the client. The 
model was developed as a unifying paradigm for defining problems, generating nursing 
care and appreciating the client in interaction with the environment. An open system may 
be a person, family, group, community or social problem (Neuman, 2011, pp. 327–329).  
Because OUD disrupts many aspects of a client’s life experience, treatment approaches 
must be holistic  
Open System  
A system in which there is a continuous flow of input, processes, output, and 
feedback. Stress and responses to stress are components of an open system, which may be 
a person, family, group, community, or social problem (Neuman, 2011, pp. 327–329). As 
clients receive treatment for OUD, a continuous exchange of input and output occurs 
from both the treatment and client systems. 
Process  
An open system exchanges energy, data, and elements in the environment and its 
parts and uses available energy to maintain equilibrium or homeostasis (Neuman, 1995; 
2011, p. 328). As an individual actively engages in treatment, their relationships, and 
environment, a process occurs that results in an exchange of energy and information.  
Feedback   
Output from the system in the form of data, energy, or matter serves as future 
input for corrective action to ensure change, enhancement, or equilibrium (Neuman, 
2011, p. 327). Persons with OUD, as well as treatment providers, use feedback to 





The function of energy conservation that assists a system to move toward stability 
or wellness (Neuman, 1995; 2011, p. 328). According to Neuman, treatment providers 
and clients must be mindful that energy conservation is necessary for the system to move 
toward wellness.  
Stability   
A dynamic and desirable state of balance and equilibrium in which energy 
exchange takes place without undue disruption of the system, enabling the system to 
move toward optimum wellness (Neuman, 1995; 2011, p. 328). As disruptions due to 
OUD resolve, the client moves toward balance, equilibrium, and stability.  
Environment  
According to Neuman, the environment is comprised of  “internal and external 
forces surrounding the client, influencing and being influenced by the client at any point 
in time” (Neuman, 1995; 2011, p. 327). The environment may influence the progression 
of OUD depending on internal and external stressors in an individual and in external 
environments.   
Client System   
Comprised of five variables (physiological, psychological, sociocultural, 
developmental, and spiritual), all of which interact with the environment (Neuman, 2011, 
p. 327).  
Lines of Resistance  
A series of permeable rings surrounding the basic structure of a system that 




line of defense (Neuman, 2011, p. 328). Clients with OUD may require bolstering of the 
normal line of defense in order to be protected from stressors.   
Normal Line of Defense   
The normal line of defense is the model’s outer solid circle (see Figure 1), which 
represents the adaptable health of a system that develops over time. Deviation from 
wellness is measured (Neuman, 1995, 2011, p. 328) against this benchmark. In OUD 
treatment, this is referred to as a client’s baseline.  
Flexible Line of Defense   
The model’s outer broken ring serves as a protective buffer for preventing 
stressors from breaking through the normal line of defense. It is also known as the first-
line protective mechanism (Neuman, 1995, 2011). The flexible line of defense is 
bolstered through engagement in treatment and utilization of supports and resources in 
the environment. 
Health   
The illness-to-wellness continuum is dynamic; optimal wellness is achieved when 
the system’s needs are met. Wellness occurs when all system subparts are interacting in 
concert with the whole system (Neuman, 1995, 2011). Ideally, health is restored when an 
individual receives effective treatment and the disease process due to OUD is stabilized.    
Illness    
The opposite end of the continuum from wellness, which represents a state of 
disequilibrium, instability, and energy depletion (Neuman, 1995, 2011). May occur when 




Stressors   
Stimuli that have the potential to disrupt system balance; the outcome may be 
positive or negative depending on interpersonal, intrapersonal, and extrapersonal forces 
(such as coping ability, support systems, and treatment access;Neuman, 1982, 1995, 
2011). Stressors exist in the client system and the environment, and may be a precipitant 
to OUD.  
Prevention as Intervention (Three Levels)   
Primary prevention is anticipation of a stressor and accounting for its risk to the 
health of a system. Secondary prevention is the utilization of interventions after 
symptoms have already developed. The client’s internal and external resources are 
mobilized in order to strengthen resistance. Tertiary prevention occurs after active 
treatment, and focuses on adaptation and adjustment toward optimum wellness as well as 
maintaining it (Neuman, 1982, 1995, 2011). All levels of prevention are utilized in OUD 
treatment, from anticipating relapse, participating in treatment once symptoms have 
developed, and stabilizing an individual and family who are experiencing advanced 
stages of OUD.   
Reconstitution   
Reconstitution occurs after treatment for negative reactions to the stressor. It 
represents the return of the system to stability prior to the stressor’s intrusion. Stability 
may be at a higher or lower level than before the system experienced the stressor 
(Neuman, 1982, 2011). The goal of treatment for OUD is to restore balance, promote 






Figure 1: The Neuman Systems Model (Copyright 1970, The Neuman systems 
model (5th ed., [page 13], Upper Saddle River, NJ: Pearson). Reproduced with the 
permission of Betty Neuman and Jacqueline Fawcett. 
 
Neuman Systems Model and Opioid Use Disorder  
Few studies exist that examine the problem of substance abuse from the 
perspective of the NSM. Several studies have been conducted that examine other health 
problems such as diabetes and dementia using the theoretical framework of the NSM.  
Research has been conducted on the education of persons with diabetes, reducing burden 
on caregivers of persons with dementia, psychosocial support of vulnerable 




Platin, 2017; Edelman & Lunney, 2000; Fawcett & Foust, 2017; Olowokere & 
Okanlawon, 2015; Sher-Pin, 2017).   
Two sources describe the development of interventions for substance abuse 
problems utilizing the NSM as a theoretical framework. Although they are not research 
studies, they discuss the generation of strategies to counter health risks due to substance 
abuse problems. Mynatt and O'Brien (1993) describe a community-based peer-assisted 
intervention program created to respond to the problem of chemical dependency among 
nurses. They implemented approaches at the primary, secondary, and tertiary levels, by 
forging community partnerships between a university, a school of nursing, local nursing 
organizations, and healthcare providers to provide services for impaired nursing 
professionals.  
 Rayan (2016) conducted a literature review on factors associated with smoking 
among Jordanian adolescents, prior to developing an intervention program to prevent and 
regulate smoking in this population. The results of the review determined the presence of 
complex physiological, psychological, sociocultural, developmental, and spiritual factors 
underlying adolescent smoking, which require prevention efforts at the primary, 
secondary, and tertiary levels identified in the NSM.  
Neuman Systems Model as a Theoretical Framework for Opioid Use Disorder 
The NSM provides one theoretical framework for this study. In this research, the 
open system of interest is the individual with OUD. In the model, individuals with OUD 
are organisms that possess basic structures such as a genetic predisposition to OUD, as 
well as response patterns unique to OUD. Further, they may possess physical strengths 




Humans often experience stressors including trauma, pain, loss, deprivation, and cultural 
change, which may modify responses to stressors. The normal defense lines may vary 
from person to person depending on age and developmental stage, as well as 
intrapersonal, extrapersonal, and interpersonal factors. An individual’s reaction to stress 
depends on their basic structure, learned resistance, and natural resistance, and the 
timing of encounter with the stressor. OUD may be viewed as a form of learned 
resistance to stressors. The nurse or HCP, using a holistic approach, assists in bolstering 
lines of resistance to stressors that reduce the risk of harm to an individual with OUD. 
The nurse may provide interventions at the secondary or tertiary prevention levels when 
the resistance lines are penetrated. The aim of interventions are to restore an individual to 
health and balance. At the level of secondary prevention, the nurse assesses the severity 
of OUD and treats the signs and symptoms that may be present. At the tertiary prevention 
level, the nurse assists an individual with OUD to adapt to an existence without opioids, 
anticipate the likelihood and risk of relapse in order to prevent it (strengthening lines of 
defense), and assists the individual to return to a state of health and maintain it once they 
no longer use opioids.  
According to the NSM, the main focus of this study was to examine the impact of 
adding tertiary prevention level variables (psychosocial treatments provided by nurses 
and HCPs) such as individual, group, and family counseling, Narcotics Anonymous-
based peer support, and other peer support, to secondary prevention level variables 
(medication treatment with BUP/NX) on several outcome variables. These include 
treatment utilization outcomes, medication utilization, opioid use, and substance use. The 






Figure 2: Neuman Systems Model in opioid use disorder treatment.  
 
Strengths and Weaknesses of the NSM   
A main strength of the NSM is its utility across a broad range of specialty areas of 
nursing including administration, education, and nursing practice. An open system is 
viewed as an individual, family, or community. It emphasizes the three levels of 
prevention and health promotion that are key principles in nursing practice. Neuman 
provides easily understood definitions of key terms (Alligood, 2014). Weaknesses of the 
model include the need for clarification of terms used, (e.g., distinction between 
intrapersonal and extrapersonal). Further, the theory does not specify meanings of lines of 




as to how accurate the model is in representing human beings and their interactions in the 
environment (Heyman & Wolfe, 2000). 
Summary of Theoretical Framework 
 Identifying OUD as a chronic neurobiological disease that presents with periods 
of relapse and remission, and has no cure implies biological treatment (medication) is 
necessary that targets symptoms and assists patient with ongoing management perhaps, 
over a lifetime (ASAM, 2011a). Furthermore, managing OUD requires patient-oriented 
and individualized treatment that targets the brain itself, as well as the changes that have 
occurred due to long-term opioid abuse.  
The NSM draws on a number of concepts from general systems theory, Gestalt 
Theory, and ideas from Neuman’s own clinical work; Neuman proposes that individuals 
are open systems interacting with one another and the environment (Neuman, 1982). The 
NSM is a dynamic, open, and systems approach to nursing care of the client with OUD. 
The NSM suggests that certain individuals possess basic structures and unique response 
patterns that predispose them to OUD. Interventions by the nurse and HCPS are aimed at 
primary, secondary, and tertiary prevention levels in order to assist persons to achieve 
reconstitution and stability through long-term management of the disorder.  
The main focus of this research was to examine the impact of adding tertiary 
prevention level variables (psychosocial treatments) such as individual, group, and family 
counseling, and self-support approaches, to secondary prevention level variables 
(medication treatment with BUP/NX) on several outcome variables. These include 






A highly addictive stimulant drug made from the coca plant. It increases the levels 
of dopamine in the center of the brain controlling pleasure. Taken in large quantities may 
result in death (NIDA, 2016a).   
Counseling and Psychosocial Treatments  
Includes individual, group, or family counseling, peer-support, and self-help 
models. Focused on halting opioid use, building coping skills, adherence to treatment and 
recovery, and preventing relapse. Available in inpatient, outpatient, residential, and 
primary care settings (SAMHSA, 2018a).  
Medication Treatment   
Medication treatment is the use of specific medications (BUP BUP/NX) 
combined with counseling and psychosocial treatments. Assists in maintaining 
abstinence, preventing relapse and opioid overdose (SAMHSA, 2018b). 
Medical Management   
Process in which healthcare professionals provide medication, brief counseling, 
monitoring of drug use, medication adherence, and referrals to other services as necessary 
to improve patient’s health (Kampman & Jarvis, 2015; SAMHSA, 2018a).  
Opioids  
Opioids are a class of drugs that include synthetic opioids, pain relievers available 
by prescription such as oxycodone, hydrocodone, morphine, and codeine, and the illegal 




Opioid Use Disorder  
A pattern of opioid use leading to clinically significant impairment. Often 
manifested by (a) opioids taken in larger amounts or longer than intended, (b) persistent 
desire or unsuccessful efforts to control opioid use, (c) a great deal of time spent in 
activities required to gain the opioid, use it, and recover from its effects, craving or strong 
desire to use opioids, among others (APA, 2013).  
Treatment Adherence   
Taking prescribed medications and following treatment plan as directed by HCP 
in order to meet treatment outcomes.   
Visit Compliance  
Attending scheduled appointments recommended by HCP on a consistent basis.  
Review of Literature 
 Research has been conducted on the effectiveness of buprenorphine (BUP), 
methadone, and naltrexone added to psychosocial treatments and medical management of 
OUD. Studies have examined the effectiveness of psychosocial treatments such as 
individual, group, and family counseling, cognitive behavioral therapy, contingency 
management, and inpatient, outpatient, and residential treatment. Findings of studies 
analyzing the addition of psychosocial treatments to BUP treatment suggest it does 
benefit some individuals with OUD. Additional research is needed, however, to 
determine the effectiveness of psychosocial treatment given that most providers of 
medication treatment require patients to receive it. Further, there is a lack of research that 
analyzes the impact of specific psychosocial treatment type on medication treatment with 




medical management along with BUP in primary care settings suggest it is highly 
effective for assisting patients to meet treatment outcomes. What follows is an analysis of 
selected studies that examine the effectiveness of psychosocial treatments, and medical 
management in primary care settings when added to BUP treatment for OUD.  
Buprenorphine and Buprenorphine/Naloxone  
Due to the actions and properties of buprenorphine (BUP), it is highly effective 
for treating OUD. It acts by lowering risk of abuse and physical dependence, possesses 
fewer withdrawal symptoms, has a high-ceiling effect at increased doses, and has 
improved safety over opioid full agonists. It is often combined with naloxone (NX) to 
reduce the potential for abuse since NX acts by blocking opioid receptors, and therefore 
blocking opiates (National Alliance of Advocates for Buprenorphine Treatment 
[NAABT], 2016; NIDA, 2017). BUP and BUP/NX are widely used and have 
significantly improved treatment outcomes for OUD. 
Buprenorphine and Psychosocial Treatment   
Several studies have evaluated the effectiveness psychosocial treatments added to 
buprenorphine (BUP) or buprenorphine and naloxone (BUP/NX). Psychologically based 
therapies are currently recommended for persons receiving medications for OUD despite 
mixed results of research findings of their effectiveness (W. Ling et al., 2013; Otto et al., 
2014; Stein et al., 2015). A variety of approaches are presently used including individual, 
family, or group counseling, cognitive-behavioral therapy, self-support groups, and 
contingency management among others (Kampman & Jarvis, 2015; NIDA, 2018g).   
The findings of several studies suggest that combining BUP or BUP/NX with 




effective for some individuals versus standard treatments such as health education or 
inpatient detoxification. For example, Berger, Pulido, Lacro, Groban, and Robinson, 
(2014) conducted a retrospective review of 30 subjects receiving BUP, who were 
assigned to one of two treatment conditions, individual counseling or group therapy. 
Subjects in group therapy had significantly greater treatment retention than those in 
individual therapy (Berger et al., 2014). In another example, Brigham et al. (2014) 
randomly assigned 104 subjects receiving BUP to one of two treatments. The first, a 
comprehensive psychosocial intervention called Community Reinforcement Approach 
and Family Training for Treatment Retention (CRAFT-T), and the other, a standard form 
of counseling. Participants receiving CRAFT-T were significantly more likely to remain 
in treatment and abstain from opioids, suggesting that adding family therapy to BUP 
benefits some individuals with OUD.   
Kosten, Poling, and Oliveto (2003) conducted a randomized, double-blind trial of 
75 subjects treated with BUP maintenance for 6 months. The subjects had been assigned 
to one of four treatment conditions: desipramine plus contingency management (CM); 
desipramine without CM; placebo plus CM; and placebo without CM. The escalation of 
CM was eliminated at 3 months. At months 5 and 6, the response required to receive 
vouchers increased to up to two and then three drug-free urine samples. The CM groups 
showed a decline in opioid and drug-free urine samples. The desipramine plus CM 
treatment arm had a significantly greater decline in drug-free urine samples than placebo. 
Subjects on BUP, and desipramine plus CM were able to abstain from illicit opioids and 




additional intervention combined with CM may be necessary in order to assist patients 
meet treatment goals.  
 Katz et al. (2011) randomly assigned 240 subjects receiving BUP at a publicly 
funded 30-day detoxification clinic to three treatment conditions: IRI (an approach to 
improve retention), IRI and case management, or standard treatment (ST). Subjects 
receiving IRI, but not IRI and case management, were significantly more likely to 
complete detox and remain in treatment longer, demonstrating the addition of counseling, 
effectively assists some patients to attain OUD treatment goals.  
The findings of two analyses of a long-term study suggests that BUP continues to 
assist subjects to remain abstinent from opioids for many months after starting BUP 
maintenance, and that psychological therapies have little added benefit to treatment with 
agonists with the addition of weekly medical management [MMT]; (Potter et al., 2015; 
Weiss et al., 2015). Potter et al. (2015) examined participants in the Prescription Opioid 
Addiction Treatment Study (POATS), a multisite, randomized trial that analyzed 
treatment outcomes of buprenorphine-naloxone treatment. A total of 252 subjects from 
the study completed an 18-month follow-up telephone assessment. Overall, participants 
were significantly more likely to remain abstinent from baseline to month 18. Further 
analysis demonstrated no significant differences in outcomes with the addition of 
psychosocial treatment to BUP and MMT (Potter et al., 2015). In another analysis of the 
POATS, Weiss and Rao (2017) found that subjects who remained on BUP were 
significantly more likely to abstain from opioids.  
Research on the effectiveness of technological interventions for delivering 




administered via computer or Internet, may be not only effective but hold promise for  
widening treatment access (Bickel, Marsch, Buchhalter, & Badger, 2008; Christensen et 
al., 2014; Reutsch & Tkacz, 2010). Bickel et al. (2008) randomly assigned 113 subjects 
receiving BUP to one of three treatment conditions: a therapist-delivered Community 
Reinforcement Approach (CRA) with vouchers (a form of CM); computer-based CRA 
with vouchers; or standard care. The therapist- and computer-delivered CRA groups 
produced comparable weeks of continuous opioid-free and drug-free urine samples and, 
significantly more weeks of abstinence than standard care. The comparable effectiveness 
of the computer-delivered intervention has implications for widening available 
treatments, an important strategy in combating the opioid epidemic.     
In another example, (Christensen et al., 2014) randomly assigned 170 adults 
receiving BUP maintenance to two treatment conditions: a community reinforcement 
intervention (CRA) delivered by computer along with contingency management versus 
contingency management alone. Subjects receiving CRA and contingency management 
were significantly more likely to abstain from using illicit opioids and remain in 
treatment. Finally, Ruetsch, Tkacz, McPherson, and Cacciola (2012) randomly assigned 
1426 participants to receive either BUP in combination with a telephone-based program 
called Here to Help (HTH), or BUP alone. Subjects in the HTH groups were significantly 
more likely to abstain from using illicit opioids. In summary, although psychosocial 
treatments added to BUP demonstrate mixed results, research suggests they are effective 
for some individuals whether delivered technologically or in person.   
While the findings of several studies suggest psychologically based therapies 




benefit to subjects. For instance, Mitchell et al. (2013) randomly assigned 300 African-
American subjects on BUP maintenance at one of two community-based clinics, to either 
outpatient counseling (OP; 3.6 hours per treatment week) versus intensive outpatient 
counseling (IOP; 5.3 hours per treatment week). No significant differences were noted 
between treatment arms in abstaining from using illicit opioids or other drugs. This 
suggests that increasing the intensity of OP may not necessarily increase the effectiveness 
of medication treatment with BUP. 
In another example, Stein et al. (2015) randomly assigned 49 adults on BUP/NX 
maintenance to receive either a 50-minute Distress Tolerance (DT) therapy session or 
standard health education (HE) over a 4-week period. The DT therapy produced a small 
but nonstatistically significant difference in illicit opioid use, suggesting psychosocial 
treatments have little added benefit to medication treatment.  
Buprenorphine and Medical Management   
Although research findings are mixed on the effectiveness of adding psychosocial 
treatments to BUP treatment, the results of studies examining delivery of BUP via MMT 
in primary care settings, suggest it is effective (Accurso & Rastegar, 2016; Fiellin et al., 
2014; Liebschutz et al., 2014; W. Ling et al., 2013; Lucas et al., 2010; Mintzer et al., 
2007; Weiss et al., 2015). In the model referred to as MMT, medication and treatment-
focused counseling are provided by a primary care physician, nurse practitioner, or other 
HCP in an office-based primary care setting (ASAM, 2015; Kampman & Jarvis, 2015; 
SAMHSA, 2018c).  
In fact, a study by W. Ling et al. (2013), underscores the effectiveness of MMT 




assigned 202 subjects stabilized on BUP for a period of 2 weeks, to four treatment 
conditions in an outpatient clinical research center for 16 weeks. Participants either 
received MMT, cognitive behavioral therapy (CBT), contingency management (CM), 
CBT and CM, or no behavioral treatment. There were no significant differences between 
groups in remaining abstinent from opioids. The researchers found no clear evidence that 
CBT or CM reduces illicit opioid use, despite that at the time of the study, the Controlled 
Substances Act required prescribers to refer patients on BUP to counseling (W. Ling et 
al., 2013). 
The findings of a study by Accurso and Rastegar (2016) further support the 
benefit of MMT combined with BUP treatment in greater than 16mg/day dosages. The 
researchers conducted a retrospective review of 297 patients receiving BUP in primary 
care for 3 or more months. Comparison groups were generated based on the dosage of 
BUP (16mg/day or lower, and 16mg/day or greater) they received. Subjects receiving 
doses greater than 16mg/day were significantly more likely to abstain from illicit opioids 
and remain in treatment than subjects receiving 16mg/day or less. The researchers 
suggest BUP delivered in higher doses is highly effective, and that lower doses may 
actually be harmful (Accurso & Rastegar, 2016).  
Fiellin et al. (2014) conducted a randomized trial among prescription opioid 
dependent subjects (n = 113) and examined the effectiveness of BUP/NX taper versus 
BUP/NX maintenance therapy delivered via MMT. Subjects on BUP/NX maintenance 
versus tapered doses were significantly more likely to submit opioid- and drug-free urine 
samples over the course of treatment. The findings suggest BUP maintenance is more 




In a cohort study, Mintzer et al. (2007) examined 99 subjects from two primary care 
settings enrolled in BUP/NX treatment for OUD. At 6 months, 54% of subjects remained 
abstinent from opioids (determined by urine drug screens). There was no significant 
correlation between abstinence and site of care, drug of choice, level of income, or 
dosage of BUP/NX. Again, the results suggest delivering BUP/NX treatment in primary 
care is highly effective. 
Moreover, the findings of a study by Cunningham et al. (2013) suggest that MMT 
combined with BUP treatment is effective in some patients for achieving abstinence from 
opioids and cocaine. The researchers analyzed the effectiveness of BUP delivered via 
MMT among opioid-dependent cocaine users versus non-users over 6 months. The 
results revealed no significant differences in treatment retention, or self-reported opioid 
use between cocaine users and non-users. The results underscore that opioid-dependent 
cocaine users benefit from office-based BUP treatment and should be included in these 
treatment programs (Cunningham et al., 2013).  
 The results of research conducted by Parran et al. (2010) suggest that BUP added 
to MMT not only targets opioid abstinence, but increases engagement in self-support 
groups, increases rates of employment and overall functioning. The researchers 
conducted a retrospective review of 110 opioid-dependent subjects who received IOP 
combined with BUP/NX for 5 weeks, followed by 12 weeks of weekly aftercare. After 
IOP, all subjects remained on BUP/NX and were referred to primary care physicians for 
MMT in an office-based setting. At an 18-month follow-up assessment, the researchers 
found subjects who remained on BUP/NX were significantly more likely to abstain from 




improved functioning. The results suggest that BUP/NX coupled with long-term MMT is 
effective not only for achieving primary treatment outcomes, but also improved quality of 
life (Parran et al., 2010).  
Additionally, the findings of two studies highlight the benefits of MMT combined 
with BUP treatment among opioid-dependent patients in targeting successful treatment of 
chronic diseases. Lucas et al. (2010) compared outcomes of BUP/NX treatment among 
93 HIV-infected, opioid-dependent subjects, delivered either in a clinic-based setting 
versus an opioid treatment program. Subjects receiving treatment in the clinic-based 
setting attended significantly more HIV primary care visits and were significantly less 
likely to submit positive UDS for opioids and cocaine. Liebschutz et al. (2014) compared 
a “linkage” intervention (BUP/NX maintenance and successful transition to office-based 
treatment) versus simple detoxification (and taper) among 139 opioid-dependent subjects 
who had been hospitalized for medical illnesses and had no prior treatment for OUD. 
Subjects in the linkage group were significantly more likely to abstain from illicit opioids 
(self-report) and remain in treatment at 6 months. This study underscores the potential of 
actively targeting opioid-dependent medically ill persons for BUP/NX treatment in 
medical settings and primary care (Liebschutz et al., 2014).  
Summary of Review of Literature 
This review examined current research on buprenorphine (BUP) treatment for 
OUD. Studies in the review analyzed the effectiveness of adding psychosocial treatments 
and medical management to medication treatment in primary care and addiction 
treatment settings. The findings suggest that medical management combined with 




opioids and treatment retention. The results of studies analyzing the effectiveness of 
adding psychosocial treatment to medication treatment are mixed. Additionally, BUP 
treatment administered in primary care settings is effective for targeting illicit use of 
opioids and cocaine among opioid-dependent cocaine users. Further, medication 
treatment improves engagement in medical treatment for co-occurring chronic diseases 







This chapter describes the purpose of the study, the research design, the use of the 
electronic health record (EHR), the study sample, setting, and limitations. Additionally, 
the constructs, methods of measurement, study procedures, data analysis, and power 
analysis are outlined. Finally, the protection of human subjects and study limitations are 
discussed.    
Purpose of the Study 
The focus of this research was to examine the relationship between individual 
counseling status and opioid use treatment outcome variables in patients receiving 
medication treatment for OUD. The outcome variables examined included treatment 
utilization, medication utilization, opioid and substance use, and treatment retention. This 
relationship was examined while controlling for important confounding variables (e.g., 
gender, age, race, ethnicity, PTSD/trauma, CJS involvement, and anxiety).  
Research Design  
A nonexperimental correlational design that utilized secondary analyses of EHRs 
was used in this study. In nonexperimental correlational research, the independent and 
dependent variables are not manipulated by the researcher (Tabachnick & Fidell, 2014, p. 
2). While it is difficult to attribute causality to an independent variable (or predictor 
variable) in correlational designs, it is  useful for describing the direction and significance 
of a relationship between an independent and dependent variable (Polit, 2014, p. 68). 




between variables (Polit, 2014, p. 216). The use of secondary data permitted the 
researcher to use extant data sources in the EHR.   
Secondary Data Analyses of EHRs    
Secondary analyses of routinely collected data such as EHRs offers an 
opportunity to gain knowledge that may improve patient outcomes (MIT Critical Data, 
2016). While collecting primary data is one of the best ways to answer research 
questions, it is not always logistically or economically feasible (Vartanian, 2011). 
“Secondary data can include any data that are examined to answer a research question 
other than the question(s) for which the data were initially collected,” (Vartanian, 2011, 
p. 3). The EHR produces and accumulates immense amounts of data, which provide 
opportunities to test hypotheses answer research questions and further advance 
healthcare. Sources of data may include outpatient and inpatient clinical notes, diagnostic 
and laboratory tests, and computerized databases among others. Some of the advantages 
and challenges of conducting secondary data analyses are described:  
Advantages of Secondary Data Analyses of EHRs  
One of the main benefits of secondary analyses is that data collection has already 
taken place and the research study completed, saving considerable time and monetary 
resources. Secondly, data may be of higher quality in EHRs since accurate documentation 
of patient data is deemed important in caring for patients. Some data sets have 
considerable breadth, permitting the selection of a sample that may be more 
representative of a target population. Large data sets also permit testing of a large number 
of variables (Koziol & Arthur, 2011). Additionally, with large data sets such as EHRs, 




modeling and hierarchical linear modeling). Large data sets often span years or months, 
permitting subjects to be studied over long periods. Researchers are able to capture 
intergenerational effects and long-terms effects of specific events and healthcare 
interventions (Vartanian, 2011).  
Disadvantages of Secondary Data Analyses of EHRs   
There are a number of pitfalls to conducting secondary data analyses on EHRs. 
The first challenge is there has been no control of what data was actually collected, and 
whether it will answer the research question being asked (Vartanian, 2011). In addition, 
there is little chance of contacting participants for additional data or follow-up 
information. Secondary data analysis may threaten the research process by encouraging 
researchers to consider only questions that can be answered by the available data 
(Vartanian, 2011). It is also important for the researcher to keep in mind, as with any data 
set, regardless of size, errors may have occurred during the data collection process that 
can negatively impact the reliability and validity of the data collected (Smith, 2008).  
Solutions to Pitfalls of Secondary Analyses of EHRs  
To offset problems with conducting secondary analyses, several strategies are 
recommended (Koziol & Arthur, 2011; MIT Critical Data, 2016; Smith, 2008; Vartanian, 
2011). These include the following: (a) Recognizing the fallibility of EHRs; that is, they 
are rarely fully complete or correct. (b) Understand bias and missing data; for example, 
selection bias may occur if subjects in the sample have sought medical care within a 
system that uses an EHR. Confounding bias is a risk in that it is difficult to account for 
confounding variables that influence the independent and dependent variables. Missing 




the results. (c) Ensure protection of patient privacy by de-identifying and safely storing 
all data. Additional suggestions for maintaining rigor of study procedures include the 
following: address sampling concerns a priori; operationalize variables; ensure 
consistency among data abstractors; develop a data abstraction procedure manual and 
procedure forms; develop well-articulated inclusion and exclusion criteria; consider intra-
rater and interrater reliability; conduct a pilot study, and attend to ethical considerations 
(Vasser & Holzmann, 2013). 
Setting and Sample 
All patient data was provided by a national office-based outpatient addiction 
treatment center that primarily provides medication treatment to patients with OUD. In 
order to receive treatment at a center, patients had to meet criteria for an opioid abuse 
disorder according to the Diagnostic and Statistical Manual of Mental Disorders (5th ed; 
APA, 2013). At each center, a biopsychosocial assessment and treatment plan was 
created for each patient. Treatment planning included individualized patient-centered care 
provided by physicians and nurse practitioners. The national treatment facility utilized an 
EHR that allowed for robust monitoring of contingency planning and management. All 
offices and all clinicians had access to this centralized EHR.  
OUDs are treated primarily with buprenorphine in a group-practice setting.  
Although most of the patients in the sample had an OUD, the treatment centers offered 
evidence-based treatment for a range of substance use disorders including alcohol, opioid 
and polysubstance use disorders among others (Bloomberg, 2016). Given the focus of the 
study, only patients who received treatment for OUD were included in analyses. Given 




treatment between January 2016 and January 2018 were included in the study. Although 
99% of the patients treated at this national facility were over the age of 18, patients under 
the age of 18 were removed from the data file prior to analyses.  
In addition to changes in treatment protocols over the past decade at the treatment 
facility, there were some differences in treatment protocol by state. For example, until 
very recently, there was no care coordination at Massachusetts sites due to state 
legislation, but in Pennsylvania, all sites had patient care coordination. Care coordination 
refers to collaborating with patients, HCPs, within the company and community agencies 
to maintain accurate information, make referrals, schedule appointments, and facilitate 
alternative or higher level care recommended by the treatment team. Since the majority of 
the sites were in Massachusetts, and care coordination had begun after January 2018, 
only patients who were seen by providers in Massachusetts were included in the analyses 
to reduce the confounding of care coordination.  
 Thus, in summary, inclusion criteria included patients treated at a national 
outpatient treatment facility who received OUD care in the state of Massachusetts 
between January 2016 and January 2018. Exclusion criteria included patients who 
received care at a treatment facility in Massachusetts due to a non-OUD primary 
substance use disorder and patients who were under the age of 18.  
Sample Size  
 An important aspect of conducting a research study is determining the sample 
size. Ideally, the sample represents the population from which it is drawn so that findings 
can then be generalized to the target population (Kadam & Bhalerao, 2010). The sample 




expected effect size, underlying rate of the condition under study in the population, and 
standard deviation in a population (Kirby, Gebski, & Keech, 2002).  
Power Analysis  
Using G*Power 3.1.9.2, a power analysis to identify the required sample size was 
performed. To estimate the necessary sample size the following parameters were used: a 
small effect size (f = 0.1), α = 0.05, 2 groups, and 5 covariates. The identified necessary 
sample size was 787. Based on information provided by the national treatment center, 
and verified by Dr. Chiodo, from January 2016 through January 2018, there is data in the 
EHR for 16,013 Massachusetts patients. Among these 16,013 patients, 13.221 were 
treated for OUD. Thus, there was ample statistical power to identify even a very small 
effect.  
Operational Definition of Variables 
The EHR contained all the information that was used in this study. The data had 
been provided to Dr. Chiodo in comma-separated values (CSV) format prior to the study. 
All CSV tables were converted to SPSS files and were merged by patient medical record 
number (MRN). All MRN and other identifying information were removed prior to data 
transfer and analysis. A description of all study variables is provided below:  
Independent Variables   
The main independent variable examined in this study was individual counseling. 
The reliability of self-reported individual counseling data was evaluated by the presence 
of scans confirming attendance at counseling visits. Based on center policy, all patients 
were required to bring in evidence of counseling activity. The evidence was scanned into 




Among the 780 patients randomly chosen, 111 patients did not meet inclusion 
criteria (e.g., did not live in MA, not a Suboxone patient, did not have lab visit data). 
Confirmation of counseling for the remaining 669 eligible patients was examined. A 
confirmed counseling scan that was present within 1 year of the last treatment date was 
identified as confirmation of current counseling. Scans confirming counseling but were 
older than 1 year from the date of the last treatment visit were identified as evidence of 
prior counseling while in treatment. Among the 669 patients, only 27.1% of the patients 
had scans present in the EHR confirming ever having attended counseling during 
treatment. Only 17.5% of the patients had scans present in the EHR confirming they 
attended counseling while in treatment. Counseling was a categorical (nominal) variable.  
Dependent Variables   
Several dependent variables were examined in this study including treatment 
utilization, medication utilization, opioid use, total time in care, time since last visit, and 
treatment retention. Although not a part of the study aims, other types of substance use 
were examined. Each variable is discussed below: 
Treatment Utilization   
Each time a patient was scheduled for a visit, an encounter is documented in the 
EHR. There are several types of visits where an encounter is created: a maintenance visit, 
a random maintenance visit, a rejoin visit, a rescheduled visit, an induction visit, a 
random urine screen visit, and other encounters (e.g., phone conversation to schedule an 
appointment). If a patient did not show for an appointment, the appointment was 
identified as a “no-show” visit. Tracking the frequency of these visits and the frequency 




are more compliant with treatment plan are considered to be progressing in treatment by 
facility treatment providers (Y.-I. Hser et al., 2016; Kampman & Jarvis, 2015, p. 11; 
Timko et al., 2016).  
In some instances, patients who returned to the facility after having discontinued 
treatment required an additional visit in order to be inducted on buprenorphine and 
naloxone, also known as Suboxone. Returning patients, depending on the length of time, 
would often be required to “rejoin” the program, which might also require another 
“initial” visit and induction visit. The number of times there was more than one induction 
visit and the number of times there was more than one initial visit, along with the total 
number of “rejoin” visits, was totaled and identified as the total number of times a patient 
had not been seen by a provider within 30 days was summed and was referred to as the 
number of care interruptions.   
Two additional treatment utilization variables were total time in care and the time 
since the last visit. Total time in care was calculated based on the number of years a 
patient was in treatment. The amount of time due to care interruptions was removed from 
the total time. Time since last visit was defined as the period of years since the last 
treatment visit.   
Medication Utilization   
Medication utilization is defined as taking medication (e.g., buprenorphine) as 
prescribed by the HCP according to the substance use treatment plan at the treatment 
center. Urine screen data was available for every visit for each patient in the EHR. OUD 
medication use was examined in this urine screen panel. Patients whose urine screens 




that visit (positive). Patients whose medication values were below standard cutoff values 
were identified as lack of medication utilization for that visit (negative). The total number 
of positive screens divided by the total number of screens performed (i.e., percent 
positive) was used in analyses.  
Opioid Use  
When patients’ urine samples were screened as indicated above, the presence of 
opioids was also investigated. Some of the opioids examined were heroin, morphine, 
hydrocodone, hydromorphone, oxycodone, and fentanyl. In addition, a general opiate 
screen was performed. Patients whose urine screens show evidence of any opioid were 
coded as positive for that visit. Patients whose medication values were below standard 
cutoff values were identified as negative for opioids. The total number of positive screens 
divided by the total number of screens performed (i.e., percent positive) was used in 
analyses.  
Retention  
The final treatment utilization variable examined was retention. A patient was 
considered in treatment if they were still receiving care at the end of the study period.  
Covariates  
In addition to the variables already presented, several covariates were available in 
the EHR. Covariates included gender, age, race, ethnicity, history of PTSD/trauma 
(yes/no), history of anxiety (yes/no), and history of involvement in the CJS (yes/no). 
During intake at the treatment facility, a patient’s gender, age, race, and ethnicity are 




Since the sample was primarily White, a White/non-White variable was constructed and 
used in analyses.  
PTSD/Trauma  
During intake, HCPs collect data on medical and social history. Data regarding 
post-traumatic stress symptoms may be entered in the EHR in free text format in several 
locations. After translating all text data to lowercase, syntax was written in order to 
identify patients with a diagnosis of PTSD. The following phrases were identified in the 
text fields and flagged as positive for PTSD: ptsd and post-traumatic stress. In addition, a 
patient with any PTSD diagnosis code was identified as positive for PTSD. Like PTSD, 
data regarding a history of trauma could be entered into the EHR in several locations. All 
of these fields were in free text format. Text from 500 patients was examined in order to 
identify specific phrases used to identify trauma in the EHR. After translating all text to 
lowercase, syntax was written to identify cases with trauma.   
The presence of trauma was also identified using text data. The following phrases 
were used: stabbed, gunshot, traumatic, abused, hostage, victim of, rape, traumatic 
abuse, childhood abuse, hx of abuse, intimate partner violence, domestic violence, gun 
shot, bullet wound, trauma hx, physical abuse, sexual abuse, emotional abuse, assaulted, 
abuse as child, stab wounds, beat up, being shot, verbal abuse, bullet lodged, shrapnel, 
stab injury, sexually abused, physically abused, mugging, traumatic experiences, 
emotionally abused, domestic violence, past sexual trauma, violent incident, abusive 
relationship, stabbing victim, molested, and kidnapped. The presence of any of these 




that indicated patients had either a history of PTSD or trauma. If one or both were present 
in the history, they were coded either yes or no for PTSD/trauma.  
Anxiety   
HCPs at the treatment facility also collect medical history regarding anxiety. 
There are several locations in the EHR where data related to a history of anxiety could 
have been entered by a provider. In addition to a diagnosis code, text fields were used to 
identify patients with a history of anxiety. After translating all text data to lowercase, 
syntax was written to identify cases with evidence of a history of anxiety.  
Criminal Justice System Involvement  
HCPs at the treatment facility evaluate patients’ involvement in the CJS (i.e., 
probation, awaiting trial, and past incarceration) each quarter when the treatment plan is 
evaluated. This data is identified via checkboxes. Providers are able to check whether 
there are “pending criminal charges” or “resolved criminal charges.” If a patient is 
positive for either, they are identified as involved with the CJS. In addition, several 
patients were identified as having CJS involvement through a separate database for 
patients who were subjects in a study being performed according to treatment center 
location. All patients in the “Jail Database” were identified as positive for CJS 
involvement. 
The final covariate used when examining several of the treatment utilization 
variables is total time in care. A patient who has been in treatment longer will by 
treatment protocol have more patient visits and more opportunities for “no show” visits. 




treatment utilization variables with the exception of analyses examining total time in care 
and time since the last visit.   
Measurement of Variables 
All variables were obtained from the EHR. The independent variable, individual 
counseling (yes/no) is nominal in scale. All dependent variables are as ratio in scale with 
the exception of treatment retention, which is nominal. 
Procedures 
 As mentioned previously, all data was provided to Dr. Chiodo in individual CSV 
data tables. Dr. Chiodo imported all data tables into SPSS and created a merged date file.  
Files were merged based on patient MRN number. Before providing the data for analysis, 
Dr. Chiodo removed all identifying patient information. IRB approval from the 
University of Massachusetts Amherst was received prior to data transfer. Once the data 
file was received, analyses were performed to evaluate study aims. 
Data Analysis 
 Prior to beginning study analyses, all variable distributions were evaluated for 
normality or data entry errors. All necessary transformations were performed prior to 
analyses. Once distribution evaluation was completed, descriptive statistics were 
calculated for all variables. Analyses by study aim are described below. The purpose of 
Aims 1 and 2 was to better understand the relationships among the variables prior to 
examining the impact of counseling. 
Aim 1   
What is the relationship between treatment utilization, medication utilization, and 




To examine the relationship between most treatment utilization variables and 
medication utilization and opioid use, partial correlations were performed. All covariates 
were included in the analyses.  
Aim 2  
Determine if medication utilization mediates the relationship between treatment 
utilization and opioid use in patients receiving medication treatment. 
For Aim 2, individual regression analyses were performed using the following 
independent variables: maintenance visits, random maintenance visits, rescheduled visits, 
other encounters, care interruptions, “no show” visits, retention, total time in care, and 
time since last visit. All covariates were entered in the first step using simultaneous entry, 
and the independent variable was entered in the second step of the regression model. In 
the third step, medication utilization was added to the regression model. For all of these 
analyses, the dependent variable was the percentage of positive opioid urine screens. To 
evaluate the presence of mediation, the change in Beta for each of the independent 
variables was examined. If there was a change in the value of the Beta from a significant 
predictor to a nonsignificant predictor, medication utilization was considered a full 
mediating factor.  
Aim 3   
Examine the impact of current and prior counseling on treatment utilization, 
medication utilization, substance use, and treatment retention.   
 To examine study Aim 3, a similar regression strategy was employed. All 
covariates were in step 1. If any of the covariates were nominal, dummy coding was 




second step. The predictor variable was individual counseling. Regression analysis was 
performed for the following dependent variables: maintenance visits, random 
maintenance visits, rescheduled visits, other encounters, care interruptions, no-show 
visits, total time in care, total time since the last visit, medication utilization, opioid use, 
and treatment retention. Since treatment retention is nominal in scale, logistic regression 
was employed.  
Aim 4   
To examine the comparative effectiveness of type of psychosocial treatment on 
medication utilization, treatment utilization, and opioid use in patients receiving 
medication treatment.  
As will be described in Chapter 4, analyses to examine Aim 4 were not 
performed.  
Protection of Human Subjects 
The secondary data set that was used for this research was information from an 
EHR from an opioid abuse treatment facility in Massachusetts between January 2016 and 
January 2018. The data was provided to Dr. Chiodo in CSV format. All CSV tables were 
converted to SPSS files and merged by patient MRN. All MRNs and other identifying 
information were removed prior to data transfer and analysis. There was minimal-to-no 
risk to subjects as the data had already been collected and analyses were performed on 
de-identified data. There was a slight risk to subjects due to loss of confidentiality. This 





Study Limitations  
There were several limitations to this research. First, given the data was derived 
from secondary data, there was a lack of control over data collected (Vartanian, 2011). 
Secondly, errors may have occurred in the data collection process and recording of 
information, which affected the reliability and validity of the data (Smith, 2008) and, 
therefore, the generalizability of findings. In addition, many participants who received 
treatment at the center, either had insurance or monetary resources to be treated for OUD, 
limiting the generalizability of the findings to other populations with OUD. Other 
limitations included necessities for participating in treatment such as transportation, the 
treatment facility dispensed two types of medication treatment, and subjects were from a 
nonrandomized sample. Finally, HCPs collected the data, thereby increasing the risk of 
interviewer bias having affected the validity of data collected.   
Strengths of the intended research included a large sample size and access to a 
data set with considerable breadth, which permits examination of a large number of 
variables. In addition, data had been collected over a long period, which permitted the 
analyses of the long-term impact of treatments under study. 
Summary 
The focus of this research study was to examine the relationship between 
individual counseling (current and prior) and opioid use treatment outcome variables in 
patients receiving medication treatment for OUD. The outcome variables examined 
included treatment utilization, medication utilization, opioid use, and treatment retention.  
A nonexperimental correlational design using secondary analysis of EHRs was 




treatment center that primarily provides medication treatment to adults 18 years and older 
with OUD. The findings of this research are expected to further advance and improve 







This chapter outlines the results of the study including sample characteristics, 
distribution evaluation, bivariate, and multivariate analyses. Multivariate analyses are 
presented for each study aim.  
Sample Characteristics 
The study sample consisted of 11,551 patients ranging in age from 19–84 years 
(mean = 38.7, SD = 10.6). After outliers for age were winsorized, the range of ages was 
19–68 years (mean = 38.7, SD = 10.5). The majority of the sample was male (58.2%), 
White (95.6%), and non-Hispanic (85.1%). Although a small number of patients resided 
in other states (1.8%), all received treatment within the state of Massachusetts. All 
patients included in this sample received buprenorphine and naloxone (Suboxone) for 
treatment of OUD.   
 Just over one quarter of the sample (28.2%) had either a PTSD diagnosis or 
reported trauma in the EHR. There was further evidence of psychiatric comorbidity as 
42.5% reported symptoms of anxiety. Just over 29% of patients (29.6%) acknowledged 
they had been involved with the CJS.  
 
Table 1: Characteristics of sample.  
Variable %  
Sex (% male) 58.2 
Race (% White) 95.6 
Ethnicity (% Non-Hispanic)  85.1 
PTSD (% yes)  13.1 
Trauma (% yes)  15.1 
Anxiety (% yes) 42.5 
CJS involvement (% yes) 29.6 





Counseling Experience  
According to patient report, 35.9% of patients received individual counseling.  
Additional types of reported counseling included group counseling (0.4%), Narcotics 
Anonymous (N/A; 4.5%), peer support (such as SMART recovery; 0.6%), and IOP 
(0.7%). Since so few patients received psychosocial treatment other than individual 
counseling, only individual counseling was examined as an independent variable.    
Table 2: Counseling patient report. 




Peer  0.6 
IOP 0.7 
Note. IOP = intensive outpatient treatment. 
As previously mentioned, the reliability of self-reported individual counseling 
data was evaluated by the presence of counseling confirmation. All patients, based on 
center policy, were required to bring in evidence of counseling activity. The evidence 
was scanned into the EHR. Confirmation of counseling attendance was examined for 669 
patients. Among the 669 patients, 27.1% had evidence of having attended counseling at 
one point in treatment. Only 17.5% of them had provided evidence of current counseling.    
Treatment Utilization and Substance Use 
Several variables were used to evaluate treatment utilization. These included the 
following: random maintenance visits (mean = 0.9, SD = 1.6); maintenance visits (mean 
= 40.8, SD = 43.3); “no-show” visits (mean = 4.6, SD = 5.3); rescheduled visits (mean = 
4.8, SD = 7.00); number of other encounters (mean = 34.6, SD = 31.4); care interruptions 




(mean = .6, SD = .7). Among patients in the sample, 43.2% had remained in treatment 
and were considered “retained.”   
All distributions were evaluated for normality and outliers. Outliers for care 
interruptions were winsorized, while the following variables were log transformed due to 
non-normal distributions: random maintenance visits, maintenance visits, “no show” 
visits, rescheduled visits, and other encounters. Transformed variables were used in all 
analyses.  
Table 3: Treatment utilization descriptive statistics. 
Variables Mean SD Min Max 
# random maintenance visits 0.9 1.6 0.0 16.0 
# maintenance visits 40.8 43.3 0.0 328.0 
# “no show” visits 4.6 5.3 0.0 62.0 
# rescheduled visits 4.8 7.0 0.0 76.0 
# other encounters 34.6 31.4 0.0 263.0 
# care interruptions 1.1 1.4 0.0 13.0 
# total time in care years 1.5 1.6 0.1 7.4 
# time since last visit 0.6 0.7 0.0 2.1 
 
Medication utilization and substance use were determined by urine drug screen 
results. Drug screens tested for the presence of Suboxone (mean = 83.5%, SD = 25.8%), 
benzodiazepines (mean = 9.5%, SD = 17.1%), alcohol (mean = 15.3%, SD = 25.1%), 
cannabis (mean = 36.7%, SD = 41.1%), amphetamines (mean = 5.2%, SD = 15.1%), 
cocaine (mean = 17.6%, SD = 28.3%), and opioids (mean = 15.1%, SD = 18.6%).  
Initially, medication utilization and substance use variables were not normally 





Table 4: Medication utilization and substance use. 
Substance (% positive) N Mean SD Min Max 
Suboxone 11326 83.5 25.8 0.0 100.0 
Benzodiazepine 11320 9.5 17.1 0.0 100.0 
Alcohol 11307 15.3 25.1 0.0 100.0 
Cannabis 11315 36.7 41.1 0.0 100.0 
Amphetamine 11317 5.2 15.1 0.0 100.0 
Cocaine 11320 17.6 28.3 0.0 100.0 
Opioids 11326 15.1 18.6 0.0 100.0 
Relationship Between Gender and Demographic Characteristics 
 The relationship between gender, race, ethnicity, PTSD/trauma, anxiety, and CJS 
involvement was evaluated via chi-square analysis (Table 5). The relationship between 
these demographic variables and age was evaluated via independent t-tests (Table 6). Due 
to high statistical power, a conservative alpha was used to evaluate statistical significance 
(α = 0.01) in a bivariate analyses.  
 Females were more likely to identify as non-Hispanic (χ2 = 160.8, p<0.001), 
report having experienced PTSD/trauma (χ2 = 251.9, p = p<0.001), and anxiety (χ2 = 
149.4, p<0.001). Males, on the other hand, were more likely to have had CJS 
involvement (χ2 = 17.4, p<0.001). There was no significant relationship between gender 
and the likelihood of identifying as White (χ2 = 3.7, p = 0.056; see Table 5). Using a more 
conservative value for alpha, there was not a significant relationship between age and 
gender (t = 4.6, p = .038).  
Table 5: Relationship between gender and demographic characteristics. 
 Gender  
χ2 
 
p  Males  Females  
Demographic     
Race (%White) 95.2 96.1 3.7 0.056 
Ethnicity (% Non -Hispanic) 81.1 90.6 160.8 <0.001 
PTSD/Trauma (% Yes) 19.1 31.9 251.9 <0.001 
Anxiety (% Yes) 37.8 49.2 149.4 <0.001 




Relationship Between Gender and Counseling Experience 
The relationship between gender and counseling was evaluated by chi-square 
analysis (see Table 6.) With respect to patient-reported individual counseling experience, 
women were significantly more likely to report having attended than males (χ2 = 120.0, 
p<0.001). Males were more likely to have attended Narcotics/Alcohol Anonymous (NA) 
(χ2 = 31.6, p<0.001). There were no significant between-group differences in counseling 
confirmation scans indicating whether patients had ever been (χ2 = 0.3, p = .600), or 
currently were in counseling (χ2 = 0.4, p = .547). Further, there were no significant 
differences in attendance at group counseling (χ2 = 0.8, p = .383), peer support (χ2 = 0.0, p 
= .908), and IOP (χ2 = 0.9, p = .337). Due to the low frequency of counseling experiences 
reported for group counseling, NA, peer support, and IOP, only individual counseling 
was analyzed.  
Table 6: Relationship between gender and counseling. 
 Gender  
 χ2 
 
p   Males  Females  
Counseling Patient Report     
Individuals Counseling (% Yes) 31.8 41.7  120.0 <0.001 
Counseling Ever Scan (% Yes) 26.3 28.1 0.3 0.600 
Counseling Current Scan (% Yes) 16.7 18.5 0.4 0.547 
Group (% Yes) 0.4 0.3 0.8 0.383 
NA (% Yes) 5.5 3.3 31.6 <0.001 
Peer Support (% Yes) 0.6 0.6 0.0 0.908 
IOP (% Yes) 0.8 0.6 0.9 0.337 
Note. IOP = intensive outpatient treatment.  
Relationship Between Gender and Treatment Utilization 
The relationship between gender and treatment utilization variables was analyzed 
via independent group t-tests (see Table 7). There was a significant relationship between 




encounters (t = -13.2, p<0.001), and total time in care years (t = -7.3, p<0.001) with 
females reporting higher rates of attendance at all three. Females, however, demonstrated 
higher rates of “no shows” (t = -8.0, p<0.001), and tendency to reschedule visits (t = -
15.7, p<0.001), while males were more likely to experience care interruptions (t = 3.4, 
p<0.01), and time since last visit (t = 3.9, p<0.001). There was no significant relationship 
between gender and attendance at maintenance visits (t = -6.2, p = .655). 
Table 7: Relationship between gender and treatment utilization. 
 
 Mean SD t p 
# random maintenance visits     
Male   0.4 0.6 
-6.9 <0.001 
Female   0.5 0.6 
# maintenance visits     
Male   2.9 1.5 
-6.2 0.655 
Female   3.1 1.5 
# “no show” visits     
Male   1.3 0.8 
-8.0 <0.001 
Female   1.4 0.9 
# rescheduled visits     
Male   1.1 1.0 
-15.7 <0.001 
Female   1.4 1.1 
# other encounters     
Male   3.1 0.9 
-13.2 <0.001 
Female   3.3 0.9 
# care interruptions     
Male   1.1 1.3 
3.4 <0.01 
Female   1.0 1.3 
# total time in care years     
  Male 1.4 1.6 
-7.3 <0.001 
  Female 1.7 1.7 
# time since last visit     
  Male 1.2 0.7 
    3.9 <0.001   Female 1.1 0.7 
Note. Log-transformed variables were not used to allow for interpretation of the values. 






Relationship Between Gender, Medication Utilization, and Substance Use 
The relationship between gender, medication utilization, and substance use was 
evaluated by independent sample t-tests (see Table 8). Women were more likely than 
men to be compliant with the medication Suboxone (t = -3.7, p<0.001). Men were 
significantly more likely than women to use alcohol (t = 7.8, p<0.001), cannabis (t = 9.5 
p<0.001), and opioids (t = 4.7, p<0.001) during treatment. Women were more likely to 
use benzodiazepines (t = -10.9, p<0.001) and amphetamines (t = -9.3, p<0.001). There 
was no significant difference between males and females in cocaine use (t = 2.7, p = .064; 
see Table 8).  
Table 8: Relationship between gender, medication utilization, and substance use. 
 Mean SD t p 
Suboxone     
 Male   58.9 17.5 
-3.7 <0.001  
 Female   60.1 16.6 
Benzodiazepine     
 Male   6.9 12.8 
-10.9 <0.001 
 Female   9.7 14.2 
Alcohol      
 Male   13.5 19.6 
7.8 <0.001 
 Female   10.7 17.3 
Cannabis     
 Male   29.1 29.2 
9.5 <0.001  
 Female   23.9 28.1 
Amphetamine     
 Male   3.4 10.2 
-9.3 <0.001  
 Female   5.5 13.5 
Cocaine     
 Male    14.3 20.8 
2.7 0.064 
 Female   13.2 20.7 
Opioids     
 Male   13.5 15.0 
4.7 <0.001  
 Female   12.1 14.5 
Relationship Between Age and Demographic Characteristics 
The relationship between age and other demographic variables was evaluated via 




gender, race, PTSD/trauma, and CJS involvement. The mean age of males was higher 
than females (t = 4.6, p = 0.038). Non-White patients were more likely than White 
patients to be older (t =- 4.2, p<0.001). Patients who reported PTSD/trauma (t = -4.4, 
p<0.001) and CJS involvement (t = 6.1, p<0.001) were also more likely to be older. 
There was no significant relationship between mean age and ethnicity (t = 9.4, p = .172) 
or anxiety (t = 1.0, p = 0.328).  
Table 9: Relationship between age and demographic variables.  
 Mean SD t p 
Gender      
 Male   39.1 10.6 
4.6 0.038 
 Female   38.2 10.3 
Race     
 White 38.1 10.4 
-4.2 <0.001 
 Non-White 40.8 12.3 
Ethnicity      
 Hispanic   40.9 10.0 
9.4 0.172 
 Non-Hispanic 38.0 10.4 
PTSD/Trauma      
 No 38.5 10.7 
-4.4 <0.001 
  Yes 39.5 9.9 
Anxiety      
 No 38.6 10.7 
-1.0 <0.328 
 Yes 38.8 10.2 
CJS Involvement      
 No 39.1 10.9 
6.1 <0.001 
 Yes 37.8 9.6 
Note. CJS = criminal justice system. 
Relationship Between Age and Counseling 
The relationship between age and treatment utilization was analyzed via 
independent t-tests (see Table 10). Given the smaller sample size for counseling scan data 
(N = 669) the traditional alpha level (0.05) was used to examine the impact of counseling 
with confirmatory (scan) data. Using the traditional level of alpha, there was a significant 




to be older than patients who did not. This relationship was found for all counseling 
variables (patient report: t = -8.2, p<0.001; ever received counseling: t = -3.2, p = 0.002; 
and evidence of current counseling: t = -2.5, p = 0.013).   
Table 10: Relationship between age and counseling patient report.  
 Mean SD t p 
Counseling Patient Report     
  No report 38.1 10.5 
-8.5 
<0.001 
  Report 39.8 10.5 
Counseling Scan Ever     
  No scan 38.4 9.9 
-3.2 
0.002 
  Scan 41.2 10.8 
Counseling Scan Current     
  No scan 38.7 10.0 
-2.5 
0.013 
  Scan 41.3 11.1 
 
Relationship Between Age and Treatment Utilization 
The relationship between age and treatment utilization variables was analyzed by 
computing the Pearson product-moment correlation coefficient (see Table 11). There was 
a significant positive correlation between increased age and attendance at random 
maintenance visits (r = 0.15, p<0.001), and maintenance visits (r = 0.13, p<0.001). There 
was a significant negative correlation between increased age and “no shows” (r = -0.14, 
p<0.001), tendency to reschedule visits (r = -0.04, p<0.001), and tendency toward care 
interruptions (r = -0.07, p=<0.01). There was no significant correlation between increased 





Table 11: Relationship between age and treatment utilization. 
 r 
# random maintenance visits 0.15*** 
# maintenance visits 0.13*** 
# “no show” visits -0.14*** 
# rescheduled visits -0.04** 
# other encounters 0.02 
# care interruptions -0.07*** 
Total time in care 0.14*** 
Time since the last visit -0.01 
**p<.01. ***p<0.001. 
Relationship between Age, Medication Utilization, and Substance Use 
The relationships between age, medication utilization, and substance use were 
analyzed via Pearson product-moment correlations (see Table 12). There was a 
significant positive correlation between age and medication utilization (r = 0.09, 
p<0.001). Older patients were more compliant with their OUD medication. Similarly, 
older patients had higher rates of benzodiazepines (r = 0.11, p<0.001) and alcohol (r = 
0.05, p<0.001). There was a significant negative correlation between age and use of 
cannabis (r = -0.19, p<0.001), cocaine (r = -0.05, p<.001), and opioids (r = -0.12, 
p<0.001). Younger patients were more often positive for these substances. There was no 
significant correlation between age and use of amphetamines (r = -0.02, p = .097).  
Table 12: Relationship between age, medication utilization, and substance use. 
 r 
Medication Adherence  
  Suboxone .09*** 
Substance Use  
  Benzodiazepine .11*** 
  Alcohol .05*** 
  Cannabis -.19*** 
  Amphetamine -.02 
  Cocaine -.05*** 





Relationship Between Counseling and Demographic Characteristics 
The relationship between counseling, gender, race, ethnicity, PTSD/trauma, 
anxiety, and CJS involvement was evaluated via chi-square analysis (see Table 13). All 
three measures of counseling were evaluated. Age was evaluated via correlation.  
When examining patient-reported counseling, females were more likely to attend 
counseling than males (χ2 = 119.9, p<.001). Those who identified as non-Hispanic (χ2 = 
9.4, p = .001) reported more PTSD/trauma (χ2 = 240.5, p<.001), reported more anxiety (χ2 
= 406.1, p<0.001), and CJS involvement (χ2 = 212.5, p<0.001) were significantly more 
likely to report attending counseling to their provider. There was no significant 
relationship between race and report of counseling (χ2 = 0.0, p = .898). There was also a 
significant relationship between age and counseling based on patient report. Patients who 
reported counseling to their provider (mean age = 39.8, SD = 10.5) were older (t = -8.5, 
p<0.001) than patients who did not report counseling to their provider (mean age = 28.1, 
SD = 10.5).  
A similar relationship was found when examining confirmed report of ever 
attending counseling and PTSD/trauma, anxiety, and history of involvement with CJS. 
Patients positive for PTSD/trauma (χ2 = 10.8, p<.001), anxiety (χ2 = 11.1, p<.001), or CJS 
involvement (χ2 = 12.1, p<.001) attended counseling more than those not positive on 
these three variables. In contrast to the patient-reported variable, counseling attendance 
when measured using confirmatory scans was unrelated to gender or ethnicity. Patients 
with evidence of any counseling while in treatment were older than those without 




A similar pattern, when compared to ever attending counseling while in treatment 
via confirmatory scale, was found when examining current counseling based on 
confirmatory scans. The only difference was there was no relationship between current 
counseling and report of PTSD/Trauma. Patients with evidence of current counseling 
were older than those without current counseling confirmation (t = -2.3, p = 0.021). 





















Gender          






  Female 58.3 41.7 71.9 28.1 81.5 18.5 
Race           






  Non-White 64.2 35.8 72.4 27.6 79.3 20.7 
Ethnicity           






  Non-Hispanic 64.2 35.8 72.9 27.1 82.3 17.7 
PTSD/Trauma           






  Yes 51.9 48.1 63.0 37.0 77.8 22.2 
Anxiety           






  Yes 53.6 46.4 66.4 33.6 76.7 23.3 
CJS History           






  Yes 54.0 46.0 58.3 41.7 74.1 25.9 
**p<0.01. ***p<0.001. 
Relationship Between Counseling and Treatment Utilization 
The relationship between patient-reported counseling and treatment utilization 
was evaluated by independent t-tests (see Table 14). Again, all three counseling measures 
were examined. Patients who reported counseling had more random maintenance visits (t 




visits (t = -2.4, p = 0.015), rescheduled visits (t = -9.3, p<0.001), and “other” encounters 
(t = -13.7, p<0.001). Patients who were in counseling were also in care longer (t = -11.4, 
p<0.001). When examining the smaller subset of patients with scanned confirmation of 
ever having counseling while in treatment, there is also significant relationship between 
many of the treatment utilization variables. In contrast to the patient report of counseling, 
there was no relationship between counseling attendance and frequency of care 
interruptions (t = -1.3, p = 0.178) or the amount of time since the last visit (t = 1.3, p = 
0.182).  
When examining confirmed current counseling, fewer treatment utilization 
variables were significant based on counseling attendance. Patients who reported 
counseling had more random maintenance visits (t = -5.0, p<0.001), maintenance visits (t 
= -13.7, p = <0.001), rescheduled visits (t = -6.6, p<0.001), and “other” encounters (t = -
10.0, p<0.001). Patients who were in counseling were also in care longer (t = -7.2, 
p<0.001). There was no relationship between counseling attendance and frequency of “no 
show” visits (t = -1.2, p = 0.884), frequency of care interruptions (t = -0.1, p = 0.888), or 
the amount of time since the last visit (t = -0.6, p = 0.182).  
When considering these relationships, it is important to understand that these 
bivariate relationships do not account for total time in care. Since the treatment protocol 
included a counseling requirement, patients who were not in counseling, might not be 





Table 14: Relationship between patient-reported counseling and treatment utilization. 
 Counseling  
 Patient Report Ever Confirmed Current Confirmed 
 Mean SD t Mean SD t Mean SD t 
# random maint. visits          






   Counseling (Yes) 0.6 0.6 0.7 0.7 0.7 0.7 
# maintenance visits          






   Counseling (Yes) 3.7 1.0 4.1 0.7 4.0 0.7 
# “no show” visits          






   Counseling (Yes) 1.5 0.9 1.5 0.8 1.5 0.8 
# rescheduled visits          






   Counseling (Yes) 1.5 1.0 1.8 1.0 1.8 0.9 
# other encounters          






   Counseling (Yes) 3.6 0.8 3.8 0.8 3.7 0.5 
# care interruptions          






   Counseling (Yes) 1.0 1.3 1.2 1.4 1.1 1.5 
# total time in care          






   Counseling (Yes) 2.1 1.7 2.6 1.7 2.5 1.7 
# time since last visit          






   Counseling (Yes) 0.5 0.6 0.6 0.5 0.7 0.7 
*p<0.05. **p<0.01. ***p<0.001. 
Relationship Between Counseling, Medication Utilization, and Substance Use 
The relationship between counseling, medication adherence and substance use 
were evaluated by independent sample t-tests (see Table 15). Again, all three counseling 
measures were examined. When examining all three counseling measures, patient-
reported counseling present in the EHR confirmed counseling ever in treatment and 
confirmed current counseling, there was a significant relationship between counseling 
and medication adherence. Patients in counseling were more adherent to medication than 
patients not in counseling (EHR report: t = -25.9, p<0.001; confirmed ever: t = -6.5, 




Analysis examining EHR patient report also revealed significant relationships 
between counseling and all substance use variables. Those who reported having attended 
counseling had higher mean levels of benzodiazepines (t = -8.1, p<0.000) and 
amphetamines (t = -8.5, p<.000), yet lower levels of alcohol (t = 2.6 p = .012), cannabis (t 
= 3.8, p<0.000), cocaine (t = 8.1, p<.000), and opioids (t = 25.5, p<0.000).  
When examining the subset of patients using scanned confirmation data, there 
was no relationship between counseling and benzodiazepine, alcohol, cannabis, or 
amphetamine use for both evidence ever in treatment (t = -1.1, p = 0.279; t = 0.5, p = 
0.616; t = 1.1, p = 0.259; t = -1.0, p = 0.318, respectively) or currently in treatment (t = -
1.3, p = 0.194; t = 0.7, p = 0.512; t = 0.5, p = 0.584; t = -0.2, p = 0.906, respectively). 
There was, however, significant relationships between counseling ever while in treatment 
and cocaine and opioids (t = 4.3, p<0.001; t = 5.1, p<0.001, respectively) or currently in 
treatment (t = 2.7, p = 0.007; t = 3.0, p = 0.003, respectively).  
Table 15: Relationship between counseling, medication utilization, and substance use. 
 Counseling  
 Patient Report Ever Confirmed Current Confirmed 
 Mean SD t Mean SD t Mean SD t 
Medication Adherence          






   Counseling (Yes) 64.1 10.3 64.8 6.2 64.2 6.9 
Benzodiazepine          






   Counseling (Yes) 9.4 13.0 9.5 13.0 10.1 13.8 
Alcohol          






   Counseling (Yes) 11.7 17.1 11.7 16.7 11.2 16.4 
Cannabis          






   Counseling (Yes) 25.6 28.0 24.3 27.8 25.0 28.2 
Amphetamine          










Cocaine          






   Counseling (Yes) 11.9 18.4 9.1 14.1 9.9 14.7 
Opioids          






   Counseling (Yes) 8.8 10.8 8.6 10.3 9.4 10.6 
*p<0.05. **p<0.01. ***p<0.001. 
Relationship Between Race, Ethnicity, and Other Demographic Characteristics  
 Most bivariate analyses regarding race and ethnicity have been provided above.  
Given the low rate of variability in both race (95.6% White) and ethnicity (85.1% non-
Hispanic), additional analyses were not performed.  
Reliability of Patient Report of Counseling 
The reliability of self-reported individual counseling data was evaluated by the 
presence of counseling confirmation (see Table 16). To determine whether a relationship 
existed between individual counseling reported by patients in progress notes, scans 
confirming current attendance at individual counseling, and scans confirming patients 
had ever been in individual counseling, chi square analyses were done.  
Results of the analysis showed there was a significant difference between patient 
report of counseling and patients with scanned confirmation of counseling.  Among the 
patients who indicated that they were currently in counseling, scanned evidence was 
available for only 33% of the patients. The significant difference suggests that the patient 
report of counseling in the EHR is not reliable.  
 
Table 16: Reliability of patient-reported counseling.   
 
Patient Report   
No Yes χ2 p 
Current Confirmation 
No 336 216 
105.8 <0.001 
Yes 10 107 
Past Confirmation 
No 292 196 
47.6 <0.001 




Analysis of Study Aims 
 Due to the lack of reliability in patient-reported data in the EHR, only confirmed 
counseling data was used in the multivariate analyses. According to the a priori power 
analyses, 787 patients were required to identify a small effect size (f = 0.1). Using a 
sample size of 669, two groups and six covariates, a small effect size (0.16) can still be 
identified as significant. Thus, there would be minimal risk of Type II error. Covariates 
included in multivariate analyses include gender (male/female), age, PTSD (yes/no), 
anxiety (yes/no), history of involvement with the CJS (yes/no), and total time in care.  
Total time in care is included as a covariate for the following treatment utilization 
variables: number of random maintenance visits, number of maintenance visits, number 
of no-show visits, number of rescheduled visits, number of other encounters, and number 
of care interruptions. Total time in care is included as the rates of these variables increase 
as a patient is in care for longer durations. Total time in care will not be used as a 
covariate when the treatment utilization variables examined are total time in care, time 
since the last visit, and retention.  
Ethnicity and race were not included in the analyses due to the large number of 
missing data and the homogeneity of variance, as discussed above. Approximately one 
quarter of the sample (25.4%) was missing data for race and 20.9% were missing 
information on ethnicity.  
Sample Comparison  
Prior to analysis of study aims, patients included in the analysis sample, patients 
whose data was evaluated via confirmatory counseling scans were compared to patients 




(treatment utilization, medication utilization, drug use). The only difference identified 
between patients included in the analysis and patients not included in the analyses was on 
time since the last visit. Patients not included had been seen more recently in care (t = -
2.12, p = 0.030). As there is a large difference in sample size, this analysis was confirmed 
by non-parametric analysis (Mann-Whitney U). There were no differences in the 
parametric and non-parametric tests.  
Table 17: Sample comparison (included and not included in aims analyses). 
 Mean SD t p 
Treatment Utilization     
  # random maintenance visits     
   Not included 0.4 0.6 
0.4 0.689 
   Included 0.4 0.6 
  # maintenance visits     
   Not included 3.0 1.5 
-1.0 0.297 
   Included 3.0 1.4 
  # “no show” visits     
   Not included 1.4 0.8 
-1.4 0.167 
   Included 1.4 0.8 
  # rescheduled visits     
   Not included 1.2 1.0 
-1.0 0.331 
   Included 1.3 1.0 
  # other encounters     
   Not included 3.2 0.9 
-0.7 0.497 
   Included 3.2 0.9 
  # care interruptions     
   Not included 1.1 1.3 
-0.6 0.520 
   Included 1.1 1.4 
  # total time in care     
   Not included 1.5 1.6 
0.3 0.728 
   Included 1.5 1.5 
  # time since last visit     
   Not included 0.6 0.7 
-2.2 0.030 
   Included 0.7 0.7 
Medication Utilization     
   Not included 59.4 17.2 
-1.5 0.147 
   Included 60.4 15.7 
Substance Use     
 Benzodiazepine     
   Not included 8.0 13.5 
-1.1 0.268 




 Alcohol      
   Not included 12.3 18.7 
0.1 0.954 
   Included 12.3 18.7 
 Cannabis     
   Not included 27.0 28.9 
0.6 0.540 
   Included 26.3 28.4 
 Amphetamine     
   Not included 4.3 11.7 
-0.1 0.920 
   Included 4.3 11.7 
 Cocaine     
   Not included 13.9 20.8 
0.3 0.787 
   Included 13.6 20.5 
 Opioids     
   Not included 13.0 14.9 
1.1 0.278 
   Included 12.3 13.7 
 
 
Analysis of Aim 1 
Aim 1. What is the relationship between treatment utilization, medication utilization, and 
opioid use in a sample of individuals with opioid use disorder receiving medication 
treatment? 
H1a: Patients with higher rate of random maintenance visit compliance will have 
increased medication utilization.  
H1b: Patients with a higher rate of maintenance visit compliance will have increased 
medication utilization.  
H1c: Patients with a lower rate of “no show” visits will have increased medication 
utilization. 
H1d: Patients with longer total time in care will have increased medication utilization.  
H1e: Patients with a lower rate of rescheduled visits will have increased medication 
utilization.  





H1g: Patients with a lower rate of care interruptions will have increased medication 
utilization. 
H1h: Patients with less time since the last visit will have increased medication 
utilization.  
H1i: Patients with a higher rate of random maintenance visit compliance will have 
decreased opioid use.  
H1j: Patients with a higher rate of maintenance visit compliance will have decreased 
opioid use.  
H1k: Patients with a lower rate of “no show” visits will have decreased opioid use. 
H1l: Patients with longer total time in care will have decreased opioid use.  
H1m: Patients with a lower rate of rescheduled visits will have decreased opioid use.  
H1n: Patients with a lower rate of other encounters will have decreased opioid use.  
H1o: Patients with a lower rate of care interruptions will have decreased opioid use. 
H1p: Patients with less time since the last visit will have decreased opioid use.  
H1q: Patients with increased medication utilization will have decreased opioid use. 
 To examine the relationship between treatment utilization variables and 
medication utilization, and opioid use, partial correlations were performed (see Table 18).  
Due to the smaller sample size, the traditional level of significance (p<0.05) was used to 
evaluate statistical significance. Results of the partial correlations showed a positive 
relationship between the number of maintenance visits, random maintenance visits, 
rescheduled visits, other encounters, total time in care, retention, and medication 
utilization after covariate control. Further, there was a negative relationship between the 




results suggest that patients who are engaged in treatment for OUD are more likely to 
take their medication.   
When examining opioid use, results revealed that higher rates of treatment 
compliance were related to lower rates of opioid use. Patients with more maintenance 
visits and more random maintenance visits had fewer positive opioid test results. Patients 
with more care interruptions and more “no show” visits, in contrast, had more frequent 
positive opioid tests. Patients who had been in care longer and had increased retention 
had fewer positive opioid results. These findings also support the hypothesis that 
increased treatment utilization is effective in reducing opioid use among patients in OUD 
treatment.  
Table 18: Relationship between treatment utilization, medication utilization,  
                and opioid use. 
 
Medication 
Utilization Opioid Use 
Treatment Utilization    
  # maintenance visitsa 0.56*** -0.25*** 
  # random maintenance visitsa 0.14*** -0.19*** 
  # rescheduled visitsa 0.17*** -0.03 
  # other encountersa 0.12** -0.01 
  # care interruptionsa -0.16*** 0.28*** 
  # “no show” visitsa 0.03 0.14*** 
  Total time in careb 0.27*** -0.37*** 
  Time since the last visitb -0.21*** 0.27*** 
  Retentionb 0.16*** -0.21*** 
**p<0.01. ***p<0.001.  
aCovariates: age, gender, PTSD/Trauma, CJS, Anxiety, and total time in care. 
bCovariates: age, gender, PTSD/Trauma, CJS, Anxiety 
 
Analysis of Aim 2 
Aim 2. Determine if medication utilization mediates the relationship between treatment 




H2a: Medication utilization will mediate the relationship between rate of random 
maintenance visit compliance and opioid use.  
H2b: Medication utilization will mediate the relationship between rate of maintenance 
visit compliance and opioid use.  
H2c: Medication utilization will mediate the relationship between rate of “no show” 
visits and opioid use. 
H2d: Medication utilization will mediate the relationship between total time in care 
and opioid use.  
H2e: Medication utilization will mediate the relationship between rate of rescheduled 
visits and opioid use.  
H2f: Medication utilization will mediate the relationship between rate of other 
encounters and opioid use.  
H2g: Medication utilization will mediate the relationship between rate of care 
interruptions and opioid use. 
H2h: Medication utilization will mediate the relationship between time since the last 
visit and opioid use.  
 To examine if medication utilization mediated the relationship between treatment 
utilization and opioid use, regression analyses were used. In this analysis, a separate 
regression was performed using each of the treatment utilization variables as a predictor. 
In each regression, all covariates were included in the first step and medication utilization 
was included in the second step. To examine mediation, the weight of the Beta coefficient 





Table 19: Evaluation of medication utilization as a mediator.  
 Opioid Use 
 Model 1 Model 2 
 β β 
Treatment Utilization    
  # maintenance visits -.37*** -.13* 
  # random maintenance visits -.22*** -.16*** 
  # rescheduled visits -.06 .01 
  # other encounters -.04 .02 
  # care interruptions .26*** .21*** 
  # “no show” visits .12** .13*** 
  Retention -.21*** -.16*** 
  Total time in care -.39*** -.28*** 
  Time since the last visit .19*** .14*** 
**p<0.01. ***p<0.001.  
Note. Model 1 provides Beta prior to entry of medication utilization.  
Model 2 provides Beta after inclusion of medication utilization.   
 
None of the analyses suggested full mediation. However, in several analyses 
where there was a significant relationship between treatment utilization and opioid use, 
the magnitude of some treatment utilization variables (maintenance visits, random 
maintenance visits, time in care, and retention) was reduced when medication adherence 
was added to the regression model. The only exception was for the number of “no show 
visits” where there is no evidence of mediation. Thus, it does appear that medication 
utilization partially mediates the relationship between treatment utilization and opioid 
use. In other words, the positive impact of treatment compliance on reduced opioid use is 
at least partially due to medication utilization.  
Analysis of Aim 3 
Aim 3. Examine the impact of current and prior counseling on treatment utilization, 




H3a:  There will be no difference in rate of random maintenance visit compliance 
between patients who are currently in counseling and those who are not. 
H3b:  There will be no difference in rate of random maintenance visit compliance 
between patients who have previously been in counseling and those who are not. 
H3c:  There will be no difference in rate of maintenance visit compliance between 
patients who are currently in counseling and those who are not. 
H3d:  There will be no difference in rate of maintenance visit compliance between 
patients who have previously been in counseling and those who are not. 
H3e:  There will be no difference in rate of “no show” visits between patients who are 
currently in counseling and those who are not. 
H3f: There will be no difference in rate of “no show” visits between patients who have 
previously been in counseling and those who are not. 
H3g: There will be no difference in total time in care between patients who are 
currently in counseling and those who are not. 
H3h: There will be no difference in total time in care between patients who have 
previously been in counseling and those who are not. 
H3i: There will be no difference in rate of rescheduled visits between patients who are 
currently in counseling and those who are not. 
H3j: There will be no difference in rate of rescheduled visits between patients who 
have previously been in counseling and those who are not. 
H3k: There will be no difference in rate of other encounters between patients who are 




H3l: There will be no difference in rate of other encounters between patients who have 
previously been in counseling and those who are not. 
H3m: There will be no difference in rate of care interruptions between patients who 
are currently in counseling and those who are not. 
H3n: There will be no difference in rate of care interruptions between patients who 
have previously been in counseling and those who are not. 
H3o: There will be no difference in time since last visits between patients who are 
currently in counseling and those who are not. 
H3p: There will be no difference in time since last visit between patients who have 
previously been in counseling and those who are not. 
H3q: There will be no difference in medication utilization between patients who are 
currently in counseling and those who are not. 
H3r: There will be no difference in medication utilization between patients who have 
previously been in counseling and those who are not. 
H3s: There will be no difference in opioid use between patients who are currently in 
counseling and those who are not. 
H3t: There will be no difference in opioid use between patients who have previously 
been in counseling and those who are not. 
H3u: There will be no difference in treatment retention between patients who are 
currently in counseling and those who are not. 
H3v: There will be no difference in treatment retention between patients who have 




To examine the impact of counseling on treatment utilization, medication 
utilization, substance use, and treatment retention, linear regression and logistic 
regression were utilized. All covariates were entered in the first step with the predictor 
entered in the second step.  
Table 20: Impact of current and past counseling on treatment utilization, medication     
      utilization, and substance use.  
 Counseling 
 Current Ever 
Treatment Utilization    
  # maintenance visits .10*** -.13*** 
  # random maintenance visits .04 .06 
  # rescheduled visits .08* .13*** 
  # other encounters .04 .09* 
  # care interruptions -.02 .03 
  # “no show” visits -.05 -.05 
  Retentiona -.14 .29 
  Total time in care .22*** .37*** 
  Time since the last visit .06 -.02 
Medication Utilization   
  Suboxone .07 .13*** 
Substance Use   
  Benzodiazepine .00 -.02 
  Alcohol -.04 -.04 
  Cannabis -.02 -.04 
  Amphetamine -.02 .02 
  Cocaine -.10* -.16*** 
  Opioids -.07 -.14*** 
*p<0.05. **p<0.01. ***p<0.001.  
aNote. Value is B (unstandardized coefficient) from logistic regression.  
 
Although a history of attending prior counseling while in treatment had a positive 
impact on medication utilization, there was not a significant relationship between 
currently attending counseling and medication utilization. Current counseling attendance 
was only related to higher rates of maintenance visits, increased total time in care, higher 
rates of rescheduled visits, and reduced cocaine use. Importantly, current counseling 




Patients who had been in counseling at some point in treatment had lower rates of 
maintenance visits, were in care longer, had higher rates of rescheduled visits, and more 
overall treatment encounters. In addition, patients who had been in counseling at some 
point in treatment, but not currently, had higher rates of medication utilization and 
reduced cocaine and opioid use. Thus, although prior history of counseling appears to 
have a positive impact on OUD treatment outcomes, current counseling had little impact 
on OUD treatment variables.   
Analysis of Aim 4 
Aim 4. To examine the comparative effectiveness of type of psychosocial treatment on 
medication utilization, treatment utilization, and opioid use in a sample of patients 
receiving medication treatment.  
This aim could not be examined given the homogeneity in counseling services 







This chapter discusses the findings of the study, implications for practice, 
limitations, and questions for future research. The main aim of this study was to examine 
the impact of counseling on several treatment utilization variables, medication adherence, 
substance use, and retention in patients in treatment for OUD.   
Some of the findings of this study will assist in patient care. For example, the 
results of this study found that patients with increased rates of treatment utilization were 
more likely to utilize medication treatment and demonstrate reduced opioid use. In 
addition, higher rates of treatment utilization were related to reduced opioid use. Further, 
patients with more frequent interruptions in OUD treatment were more likely to test 
positive for opioids.  
Women in OUD treatment were more likely to have experienced PTSD/trauma, 
and anxiety, while males were more likely to have CJS involvement. Women in this 
study were more likely to be retained in care, and were in treatment for a longer length of 
time than males. In addition, older patients were more likely to utilize their medication 
than younger patients were; however, they were also more likely to use benzodiazepines 
and alcohol.  
There was very little evidence that counseling during OUD treatment had a 
positive impact on treatment utilization. And there was no evidence that counseling while 
active in treatment had an impact on medication utilization or opioid use. Although 
counseling may have some benefit for some patients in OUD treatment, the findings of 




Relationship Between Gender and Demographic Variables 
 The findings of bivariate analyses of gender and demographic variables suggest 
that females were more likely to identify as non-Hispanic and to report having 
experienced PTSD/trauma and anxiety, while males were more likely to have 
experienced involvement with the CJS. The analyses found no significant relationship 
between gender and identifying as White.  
Given the lack of diversity among women in the study population, the question 
arises as to whether persons of diverse backgrounds have adequate access to treatment for 
OUD. A recent study based on nationally representative data from ambulatory medical 
care surveys found that White persons, those who can pay out of pocket or have private 
insurance, are more likely to receive opioid treatment with buprenorphine (Lagisetty, 
Ross, Bohnert, Clay, & Maust, 2019). Very often, demographics determine the choice of 
medication rather than the extent and severity of an individual’s OUD (Manhapra, 
Quinones, & Rosenheck, 2016).   
It is noteworthy that women in medication treatment for OUD were more likely to 
have experienced PTSD/trauma and anxiety. This is consistent with previous research 
(Back et al., 2011; A. Campbell et al., 2018; Greenfield, Back, Lawson, & Brady, 2010; 
Huhn, Berry, & Dunn, 2019; S. Ling, Mangaoil, Cleverley, Sproule, & Puts, 2019). In 
fact, A. Campbell et al. (2018) and Huhn et al. (2019) recommend the utilization of 
gender-specific interventions for women with OUD, co-occurring mental health disorders 
and trauma in order to address the unique needs of this population. Women were more 
likely than men to have scans confirming current and prior counseling in the EHR. Given 




that may interfere with daily functioning, one would expect these patients to have sought 
counseling.  
In contrast, males were more likely to have been involved with the CJS. It is 
noteworthy that patients who were involved with the CJS were also more likely to have 
confirmation scans of present and prior counseling in their EHR. Often persons in the 
CJS enter diversion programs that permit them to seek treatment as an alternative to 
incarceration (SAMHSA, 2019b). Furthermore, it is highly recommended that a 
successful collaborative relationship between treatment systems and the CJS exist since 
treatment must be individualized to the CJS and the client’s stage in recovery (SAMSHA, 
2005). This may explain, in part, the reason these patients were more likely to be in 
current or prior counseling.  
Relationship Between Gender, Counseling, Treatment Utilization, and Substance 
Use 
In relation to gender and treatment utilization, women were more likely than men 
to attend random visits, other encounters, and spend more time in care, which are 
indicators of treatment utilization. Previous research suggests women are more likely to 
be retained in treatment than their male counterparts (Saxon et al., 2013; Weinstein et al., 
2017). Conversely, women were more likely to “no show” for visits and reschedule visits, 
while males were more likely to have treatment interruptions. Weinstein et al. (2017) 
caution that although women may have better retention in outpatient treatment for OUD, 
there remains a great deal of stigma that prevents women from fully engaging in 
treatment. In addition, women may lack childcare and are concerned with losing custody 
of their children should their history of opioid use be revealed (Tuchman, 2010). They 




mothers with children. They also are more likely to live with a partner who is using 
substances (Bawor et al., 2015). These factors may result in more treatment interruptions 
for women, which may explain, increased “no shows” and the rescheduling of treatment 
visits.   
With respect to medication compliance and substance use, women were more 
likely to adhere to medication treatment, yet test positive for benzodiazepines and 
amphetamines, a finding consistent with previous research (Back et al., 2011). Evidence 
exists that women are more vulnerable to the rewarding effects of stimulants and that 
estrogen is possibly a factor in this sensitivity (Anker & Carroll, 2011; NIDA, 2018f). 
Also, women are more at risk for anxiety (A. Campbell et al., 2018; NIMH, 2016) and 
often are prescribed anti-anxiety medications, which in turn increases access and misuse 
(NIDA, 2018f). Men, on the other hand, were more likely to test positive for alcohol, 
cannabis, and opioids during medication treatment for OUD. This is consistent with 
previous research on substance abuse in males (A. Campbell et al., 2018; NIDA, 2018f; 
SAMHSA, 2017). Several researchers have suggested that since there are a number of 
differences in treatment outcomes for women that are not well understood, more research 
is needed in this area (Back et al., 2011; Huhn et al., 2019).  
Influence of Age on Patient Characteristics and OUD Outcome Variables 
There were significant relationships between age and several patient 
characteristics including gender, race, PTSD/trauma, and CJS involvement. Males and 
non-Whites were more likely to be older. Interestingly, older patients were more likely to 




years comes an increased risk of major life events that may have necessitated counseling 
at one time or another.  
In terms of treatment utilization, attendance at random maintenance and 
maintenance visits increased with age as well. Increased age was related to fewer 
treatment interruptions, while younger patients were more likely to have treatment 
interruptions. Young adults ages 18–25 are known to be the largest group to abuse 
prescription opioids, stimulants, and anti-anxiety agents (CDC, 2018). Future studies 
aimed at identifying specific interventions that will better engage young persons in opioid 
use treatment would be useful since the problem of opioid use is rapidly increasing 
among this population.   
The findings suggest that older individuals are more likely to utilize their 
medication. In addition, the use of benzodiazepines and alcohol increased with age, while 
the use of cannabis, cocaine, and opioids was more common in younger patients. In fact, 
the misuse of tranquilizers and sedatives has been increasing among older adults in recent 
years and presents a number of significant dangers associated with it. Olfson, King, and 
Schoenbaum (2015) conducted a retrospective descriptive study on a prescription 
database that included 60% of all retail pharmacies in the United States. Their findings 
suggest that despite risks associated with long-term benzodiazepine use, it remains 
common in older adults. Furthermore, among the 5.2% of adults aged 18–80 who used 
benzodiazepines in 2008, the largest percentage (8.7%) occurred among 65–80 year olds. 
Further, Schepis and McCabe (2019) used data from the 2009–2012 National Survey on 
Drug Use and Health, and found that older adults (ages 50 and older) had increased 




ideation). Their findings suggest that tranquilizer/sedative misuse has a unique pattern 
among older adults and is largely understudied.  
Relationship Between Patient Characteristics and Counseling  
Patients who identified as non-Hispanic, had a past history of PTSD/trauma, 
anxiety, and CJS involvement were more likely to be in current and prior counseling. 
Older patients were also more likely to have confirmation of current and prior counseling. 
There was no relationship between race and current or prior counseling. As noted 
previously, there was minimal variance in race. Patients with PTSD/trauma, anxiety, and 
CJS involvement were more likely to have scans confirming prior counseling. No 
significant relationship was found between gender and current or prior counseling.  
Analysis of Study Aims 
Aim 1  
The purpose of this aim was to examine the relationship between treatment 
utilization (maintenance visits, random maintenance visits, rescheduled visits, other 
encounters, care interruptions, “no show” visits, total time in care, time since last visit, 
and retention) and medication utilization and opioid use. It was hypothesized that patients 
with higher rates of treatment utilization would be more likely to utilize their medication. 
The findings suggest that patients who had increased maintenance visits were more likely 
to utilize medication, be retained in treatment, and have reduced opioid use. The 
hypotheses were supported by the results (Table 21). This finding highlights the 
importance of engagement in treatment in order to promote medication adherence, which 
is essential in preventing relapse. The importance of Suboxone utilization (and other 




effectiveness in reducing opioid use is widely known (Fiellin et al., 2015; Hser et al., 
2014; Kamien, Branstetter, & Amass, 2008; Mariolis, Bosse, Martin, Wilson, & Chiodo, 
2019; Rosenthal et al., 2013).    
Given the importance of OUD treatment and medication utilization, it is 
concerning that both are widely underutilized due to poor access. In order to increase 
access, there has been movement toward getting physicians in primary care and other 
medical settings to provide office-based treatment, along with Suboxone and other 
medications for OUD. Offering treatment in primary care settings has been shown to 
reduce attrition in opioid use treatment. Presnall, Wolf, Brown, Beeler-Stinn, and Grucza 
(2019) conducted a study in which they found the utilization of medication treatment 
reduced dropout rates, OUD-related ED visits and hospitalizations, and treatment in 
office-based settings was even more effective in reducing negative outcomes related to 
OUD. 
Additionally, the results of recent studies suggest that treatment utilization and 
buprenorphine are effective for persons with OUD and co-occurring chronic diseases. In 
a recent retrospective cohort study designed to quantify the effect of buprenorphine on 
adherence to five therapeutics classes of medications, the researchers found 
administration of buprenorphine in office-based treatment was associated with greater 
odds of adherence to antilipids, antiepileptics, and antidepressants (Chang, Daubresse, 
Saloner, & Alexander, 2019). They concluded that using medication treatment for OUD 
may increase adherence to medications for many chronic diseases and that this is 
especially important given the high rates of comorbidities in populations with OUD.  




improves medication adherence, but holds promise for patients with OUD and co-
occurring medical conditions. It is concerning, however, that only one third of outpatient 
treatment centers provide treatment for OUD, chronic diseases, as well as infectious 
diseases (Jones et al., 2019). Thus, reduced access is a barrier for OUD patients with co-
occurring medical and infectious diseases as well. 
Table 21: Summary table of partial correlations between treatment utilization,  
 medication utilization, and opioid use. 
 
Medication 
Utilization Opioid Use 
Treatment Utilization    
  # maintenance visits + - 
  # random maintenance visits + - 
  # rescheduled visits +  
  # other encounters +  
  # care interruptions - + 
  # “no show” visits  + 
  Total time in care + - 
  Time since the last visit - + 
  Retention + - 
+ or - = a relationship between treatment compliance or drug use and IV’s.  




Aim 2   
The objective of Aim 2 was to determine if medication utilization mediated the 
relationship between treatment utilization and opioid use in patients receiving medication 
treatment. It was hypothesized that medication utilization would mediate the relationship 
between treatment utilization and use of opioids. As stated earlier, although none of the 
results suggested full mediation, medication utilization had a very small impact on 
increasing maintenance visits; however, the effect size was very small (Table 22). The 
hypotheses for this aim were not supported by the results. Although treatment utilization 




OUD treatment is associated with early treatment dropout and poor treatment outcomes, 
and therefore, continues to be a target of OUD treatment (M. Campbell, Kolodner, 
Spencer, & DuPont, 2016).  
In the recent M. Campbell et al. study (2016), the researchers found that 
nonprescribed opioid and drug use during maintenance treatment is highly correlated 
with lowered retention and risk of early treatment termination. Patients in maintenance 
treatment with at least one positive drug test left treatment 6 months sooner, on average, 
than those with no positive drug tests and were twice as likely to leave without 
completing continuing care (87% to 42%; M. Campbell et al., 2016).  
The Ronquest, Willson, Montejano, Nadipelli, and Wollschlaeger (2018) study 
found that remaining on buprenorphine (BUP) after the discontinuation of OUD 
treatment continues to prevent relapse and reduce medical costs in patients. They 
determined that BUP adherence in the 12 months following treatment for OUD reduced 
the odds of relapse and unadjusted medical costs for patients. After adjustment, total 
costs of adherent patients with commercial insurance were significantly lower than non-
adherent patients (Ronquest et al., 2018). The results of this current study underscore the 
importance of medication adherence in reducing relapse and its negative health 
consequences.  
Aim 3.  
The objective of this aim was to examine the impact of current and prior 
counseling on treatment utilization, medication utilization, and opioid use. The findings 
indicate there was not a significant relationship between current attendance at counseling 




positive impact on treatment utilization (total time in care), medication utilization, 
reduced cocaine use, and reduced opioid use; however, the effect sizes were very small.  
The findings suggest that while current counseling may have some benefit for some 
patients in OUD treatment, the results of this study found no evidence that supports the 
current policy that requires patients to be in counseling during treatment.  
Table 22: Summary table of relationship between current and prior counseling on 
treatment utilization, medication utilization, and substance use.  
 Counseling 
 Current Ever 
Treatment Utilization    
  # maintenance visits + - 
  # random maintenance visits   
  # rescheduled visits + + 
  # other encounters  + 
  # care interruptions   
  # “no show” visits   
  Retention   
  Total time in care + + 
  Time since the last visit   
Medication Utilization   
  Suboxone  + 
Substance Use   
  Benzodiazepine   
  Alcohol   
  Cannabis   
  Amphetamine   
  Cocaine - - 
  Opioids  - 
+ or - = a relationship between treatment compliance or drug use and IV’s.  
 Unless otherwise noted, +/- apply to all variables. 
 
Results of prior studies on the impact of counseling in OUD treatment are mixed. 
For example, Moore et al. (2016) conducted a secondary analysis of a 24-week 
randomized trial of physician management or physician management plus cognitive 




patients and examined whether outcomes differed between the groups. While opioid 
abstinence and retention did not differ according to opioid use group (heroin or 
prescription opioids), the type of opioid moderated the effect of CBT on negative urine 
samples for all drugs. Prescription opioid use patients assigned to physician management 
combined with CBT had more than twice the mean amount of abstinence from all 
substances. The researchers suggest that closer examination of additional factors that 
predict response to CBT and other behavioral interventions may shed light on response to 
various interventions. The results suggest that prescription opioid patients responded 
better to counseling, specifically physician management and CBT, than heroin users. This 
is an important consideration in the development of treatment plans for prescription 
opioid patients and heroin users in clinical practice.  
Conversely, a well-known randomized controlled trial conducted by W. Ling et 
al. (2013), compared the effectiveness of combining BUP with four types of behavioral 
treatments: CBT; contingency management (CM); both CBT and CM; and no behavioral 
treatment. The primary outcome was urine tests for opioid use; additional outcomes 
included retention, withdrawal symptoms, craving, other drug use, and adverse events. 
The researchers found no differences among the groups in opioid use. They concluded 
there was no clear evidence that CBT or CM reduce opioid use when combined with 
BUP and medical management (W. Ling et al., 2013).  
Carroll and Weiss (2017) conducted a systematic review of randomized controlled 
trials in order to examine what constitutes appropriate counseling in OUD treatment. 
They reported that four key studies demonstrated no benefit from adding counseling to 




types of behavioral counseling and contingency management (CM). They concluded that 
while high-quality medical management works for some patients with OUD, retention 
rates at 6 months seldom reached above 50%. Additionally, poor treatment outcomes 
were associated with dropping out of treatment. They suggested more evidence is 
required to determine for whom medical management is sufficient, and to develop 
strategies to better retain individuals in OUD treatment with BUP (Carroll & Weiss, 
2017).   
Additionally, Fiellin et al. (2013) conducted a 24-week randomized controlled 
trial with 141 patients in primary care, office-based buprenorphine/naloxone treatment to 
determine the impact of behavioral therapy on treatment outcomes. Patients were 
randomly assigned to receive physician management or physician management plus 
CBT. The primary outcomes were self-reported opioid use, abstinence from opioid use 
determined by urine tests. The two treatment conditions had similar effectiveness in 
reducing self-reported opioid use. The researchers reported that among subjects in the 
study sample, the effectiveness of the two interventions did not differ significantly 
(Fiellin et al., 2013). 
Finally, Sofuoglu, DeVito, and Carroll (2019) conducted a nonsystematic review 
in order to examine OUD treatments, key pharmacological and behavioral interventions, 
their mechanism of action, effectiveness, clinical practice guidelines. They also wanted to 
identify specific approaches to co-occurring medical conditions during OUD treatment.  
They concluded that while medication treatment is an effective first-line approach to 
OUD for patients with psychiatric comorbid conditions, it is more effective when 




psychiatric symptoms that can potentially reduce the effectiveness of medications for 
OUD (Sofuoglu et al., 2019). In addition, the researchers recommended future studies 
that examine treatments for patients with OUD and psychiatric conditions. 
The results of the current study do not provide evidence for policy that mandates 
counseling while in treatment. Requiring counseling during OUD likely reduces access to 
treatment and presents a barrier for patients who may benefit from medication alone. 
Given that attending counseling presents a hardship for some patients, due to lack of 
resources such as transportation, and childcare, among others, clinicians should question 
if counseling is necessary. Restriction of care might be more harmful than not receiving 
counseling during OUD treatment. In addition, in the future, it also might be beneficial to 
utilize other mechanisms of evaluating the influence of counseling on care such as the 
level of patient functioning (e.g., maintaining a stable home, employment, avoidance of 
criminal behavior, and successful management of medical and mental health conditions) 
(Carroll & Weiss, 2017). Other factors to take into account are a patient’s motivation, 
financial resources, family support, and severity of opioid disorder and co-occurring 
medical and mental health illnesses. Requiring all patients in OUD treatment to attend 
counseling carries the serious risk of becoming a barrier to treatment, thereby reducing 
access to care for those who need it.   
In summary, the findings of Aim 3 suggest that attending counseling during 
treatment for OUD has minimal impact on treatment utilization, does not improve 
medication utilization, and does not reduce opioid use. Requiring patients to attend 




barrier to treatment, increases the treatment burden, and limits access to patients who 
need it.   
Application to Theory 
As explained in Chapter 2, the complexity of OUD precludes it from being clearly 
understood from the perspective of a single theory or conceptual framework. This study 
utilized two theoretical viewpoints to grasp the complex nature and progression of OUD. 
First, OUD was examined from the viewpoint that it is both a neurobiological illness and 
a chronic disease that requires continuous management by patients, nurses, and HCPs 
over long periods, or perhaps over the course of a lifetime. As with other chronic 
diseases, OUD presents with periods of relapse and remission, and has no cure. Goals of 
treatment should include self-management and an individualized, patient-oriented plan of 
care to assist patients to cope effectively with urges and reduce the potential for relapse.  
First, the Neuman Systems Model provided a theoretical framework for 
comprehending OUD in the context of multiple contributing factors. The NSM is a theory 
that puts forth the notion that individuals are open systems interacting with one another 
and the environment (Neuman, 1982). The theory suggests that, in order to maintain 
health, an individual must continually adapt to its environment. Should an individual face 
undue stress, the balance and stability of an “organism” is threatened; therefore, 
adjustment to stressors is a continuous and active process. The variables that determine 
successful adaption, may be physiological, psychological, sociocultural, developmental, 
or spiritual (Neuman & Fawcett, 2011). Neuman views individuals as possessing a core 
structure that is safeguarded by lines of resistance. An individual’s level of health is 




time, NLD becomes overtaxed, a flexible line of defense (FLD) protects it. Should the 
FLD interact with an intense stressor, the system goes into a state of disequilibrium, 
thereby becoming unstable (Neuman & Fawcett, 2011). As this occurs, lines of resistance 
are activated, increasing the likelihood for the system to move into a state of illness. If the 
system possesses adequate energy and support, it will re-stabilize and the NLD will be 
restored to either its original state or improved from its previous state (Gonzalo, 2011). 
The results of this study suggest that nurses and HCPs should first use medication 
(a secondary prevention) to treat symptoms of OUD. Given the extent to which long-term 
use of opioids can cause significant changes in the brain that impact affect, motivation, 
and impulsivity, as well as result in a chronic disease process, a pharmacologic approach 
is necessary. Once symptoms are relieved, the nurses intervene at the tertiary level to 
strengthen lines of defense and lines of resistance that prevent stress from increasing the 
risk of further harm due to relapse in an individual with OUD. At the tertiary prevention 
level, the nurse or HCP assists an individual with OUD to adapt to an existence without 
opioids (with counseling), to anticipate the likelihood and risk of relapse in order to 
prevent it, and to return to a state of health and maintain it once the individual no longer 
uses opioids. These study results support the use of both theoretical viewpoints as a basis 
for providing care for OUD.  
The aim of the study was to examine the impact of adding tertiary-prevention-
level variables (i.e., counseling) to secondary-prevention-level variables (medication 
treatment with buprenorphine and naloxone) on several outcome variables. These include 
medication utilization, treatment utilization, and substance use. The extent to which an 




whether successful adjustment to stress occurs. At the secondary prevention level, 
medications such as Suboxone stabilize the neurobiological changes in the brain that 
occurred due to OUD, so that adaption to the absence of opioids can take place. At the 
tertiary prevention level, treatment utilization and counseling bolster one’s coping ability 
in order to adapt to life without opioids. The result is improved health and stabilization.  
Implications  
As stated earlier, the findings of this study indicate that attending counseling 
during treatment for OUD has minimal impact on treatment utilization, does not improve 
medication utilization, and does not reduce opioid use. In examining this finding in the 
context of studies done by other researchers, this has several implications for clinical 
practice. First, while previous research suggests that intensive OUD treatment combined 
with BUP and specific behavioral interventions (CBT, CM with escalating vouchers, 
among others) are effective for many patients with OUD (Bickel et al., 2008; Christensen 
et al., 2014), the present study did not find a meaningful relationship between counseling 
and OUD treatment outcomes. Policy requiring OUD patients to attend “counseling” may 
actually be harmful. As stated earlier, due to a lack of resources (monetary, 
transportation, and childcare), some patients simply are unable to attend counseling.  
Therefore, requiring counseling increases the risk of becoming a barrier to treatment, thus 
reducing access to treatment. Requiring counseling restricts access, increases treatment 
burden, and may not be necessary for all patients.   
In addition, clinicians should pay attention to the unique needs of women in OUD 
treatment. The findings of the present study suggest women are more likely to adhere to 




consistent with previous research (Back et al., 2011). Also, the women in this study had 
higher rates of anxiety and PTSD/trauma than males. According to A. Campbell et al. 
(2018), women are often prescribed anti-anxiety medications, which in turn increases 
access and misuse (NIDA, 2018f). Clinicians should actively respond to the unique needs 
of women in OUD treatment, including ensuring they receive treatment for anxiety, and 
PTSD/trauma and anxiety. Further, they should identify the inappropriate use of 
benzodiazepines and stimulants in women. Finally, clinicians must assist women to 
address barriers to treatment and the potential stigma in seeking treatment.  
 The results of this study suggest that use of benzodiazepines and alcohol increases 
with age. As mentioned earlier, the misuse of tranquilizers and sedatives has been 
increasing among older adults in recent years and presents a number of significant 
dangers associated with it (Olfson et al., 2015). This has occurred despite risks associated 
with long-term benzodiazepine use. One major health risk associated with misuse of 
sedatives and tranquilizers is suicidal ideation. Also, research suggests that 
tranquilizer/sedative misuse has a unique pattern among older adults that has been largely 
understudied (Schepis & McCabe, 2019).  
 Clinicians treating older adults for OUD and other chronic conditions should 
screen older adults for misuse of benzodiazepines and sedatives given the health risks 
these substances pose to this population. Given that older adults are at higher risk for 
depression and suicide than other populations, and that misuse of these substances can 
result in suicidal ideation, older adults must be carefully assessed for both. Further, they 




 Lastly, given the importance of treatment utilization, medication adherence, and 
treatment retention in preventing relapse of OUD, clinicians should actively work to 
improve retention especially in office-based treatment and outpatient treatment centers 
(Carroll & Weiss, 2017). Given that retention rates are about 50% in office-based OUD 
treatment, and risk of relapse, overdose, and death are associated with dropout (Fiellin et 
al., 2014), it is essential that clinicians work steadily toward increasing retention. In 
addition, clinicians should continue to actively increase access to OUD treatment for 
highly complex patients and those with co-occurring mental health disorders, chronic 
medical problems as well as infectious diseases. 
Implications for Nursing 
 An important implication for nurses who work with patients with OUD is to 
utilize the most current evidence when formulating treatment plans. This is essential in 
that present policies lack evidence that counseling is necessary even though it is 
mandated by insurance companies and clinicians. By using evidence, patients have 
increased chances of achieving treatment outcomes and not wasting time on ineffective 
treatment models.    
Also, nurses can have a unique role in reducing the misuse of prescription 
opioids. According to the ANA (2018), nurses have an opportunity to lead the way in, 
“an attitudinal transformation toward pain management.” (ANA, 2018, p. 2). The ANA 
has commended steps put forth in The National Pain Strategy that focus on the following:  
prevention, recognition, and intervention of pain issues in primary care settings; a person-
centered interdisciplinary approach to pain management; and support for pain self-




leadership, and executive roles, they are in pivotal positions to assist patients and families 
weigh the risks and benefits of treatment options for pain. In the role of advocate and 
educator, working closely with patients, they can encourage the use of non-opioid pain 
management, such as other drug treatments, anesthetic interventions, surgery, counseling, 
physical therapy, and complementary and alternative medical treatments (ANA, 2018). 
 Nurses, nurse practitioners (NPs), and HCPs must be active at the state level in 
order to promote legislation being passed that lessens restrictions on the scope of practice 
for NPs and reduces the significant shortage of professionals authorized to prescribe 
medications for OUD. For example, six states in the United States with high levels of 
opioid use have strong restrictions on NPs to prescribe medications that can significantly 
help treat the problem (Maier, 2019). According to Spetz, Toretsky, Chapman, Phoenix, 
and Tierney (2019), these states should reform their regulations in order to take full 
advantage of the available workforce in addressing the opioid crisis. After examining 
state-level data on the number of Drug Addiction Treatment Act waivers for physicians, 
NPs, and physician assistants, they found the mean percentages of NPs with waivers was 
5.58% in less restrictive states and 2.44% in more restrictive states. The researchers 
suggest that if collaboration, supervision, and scope of practice restrictions cannot be 
changed, states should work to connect NPs with physicians who are willing to supervise 
them in treating patients with buprenorphine (Spetz et al., 2019).  
 For NPs who do prescribe medications for OUD, several steps can be taken to 
address prescription opioid use by improving safe and appropriate prescribing. (ANA, 
2018). The steps include improving clinical education and decision making to reduce 




technology to support proper pain management; and utilizing best practices to increase 
safe prescribing.  
Finally, the International Nurses Society on Addictions (IntNSA), an organization  
dedicated to improving the well-being of individuals and families impacted by substance 
use, recently worked to outline a plan for increasing opportunities for nurses around the 
globe to collaborate in order to improve the response to addiction at all levels. In this 
way, it is now possible for the membership to effect change and improve treatment at 
local, organizational, national, regional, and international levels (Clancy & Fornili, 2019).   
Limitations 
There were several limitations to this research. First, given the data was derived 
from an EHR, there was a lack of control over its integrity. Secondly, HCPs are subject to 
human error when documenting patients’ history and assessment findings, which could 
have affected the reliability and validity of the data, limiting the generalizability of the 
findings. In addition, during the data collection process, there was the risk of interviewer 
bias affecting the validity of data collected.   
Another concern was the reliability of patient-reported data. Analysis of the data 
suggested there was a significant difference between patient-reported counseling and data 
that was based on confirmatory scans of current and prior counseling. Of patients who 
reported receiving counseling, only 39.1% had confirmation scans of current counseling. 
Among patients who reported receiving counseling, only 40.2% had confirmatory scans 
of prior counseling.   
Also, patients treated at the centers in this study likely had either insurance or 




lack of racial and ethnic diversity in the study sample, limiting generalizability of 
findings to populations vulnerable to OUD and those least likely to get treatment. Other 
limitations included the requirements for participating in treatment, namely 
transportation. Additionally, the study examined patients who took one type of 
medication, and who were from a nonrandomized sample. Another important limitation 
was that patients were required to attend counseling as part of the treatment protocol. The 
result may support the addition of counseling in the analyses.     
Questions for Future Research 
The results of this study pose several areas for future research. In this study, 
counseling during treatment for OUD had minimal impact on treatment utilization and no 
impact on medication utilization or opioid use, two key outcomes of treatment. However, 
previously attending counseling at some point in treatment did have a positive impact on 
medication adherence, reduced opioid use and cocaine use. Research examining the 
underlying mechanisms for this difference would be useful. This understanding may also 
assist in the identification of specific patient populations for whom counseling is 
beneficial, and patient populations who do not benefit from counseling while in OUD 
treatment. Additional research on improving retention in office-based treatment is 
necessary given the high attrition rates after 6 months. Studies that examine the benefits 
of utilizing functional outcomes as indicators of treatment response, as opposed to 
retention and urine screens alone, could widen measures and definitions of treatment 
success in OUD treatment. Also needed are studies on subgroups of patients who are 




opioid use, complex patients, and patients with co-occurring mental health conditions, 
medical diseases, and infectious diseases.  
Future research should focus on the unique needs of women in OUD treatment, 
especially those with anxiety, PTSD/trauma, other co-occurring conditions and reduced 
access to care. Also, exploring ways to increase access to the best choice of medication 
treatment for OUD regardless of ethnicity, race, and ability to pay is needed. Finally, 
additional research on the misuse of benzodiazepines and alcohol among older adults 
would be beneficial since this problem has recently increased, and has a unique pattern 
and dangerous health consequences.    
Conclusion 
The purpose of this research was to examine the impact of psychosocial 
treatment, specifically counseling, on medication utilization, treatment utilization, opioid 
use, and treatment retention in patients who had received treatment for OUD. Current 
counseling attendance did not have a significant impact on treatment utilization, 
medication utilization, or drug use. Although current counseling was not significant, 
counseling at some point in treatment had a positive impact on treatment utilization and 
medication utilization and reduced both cocaine use and opioid use. It may be that 
counseling is also more important for some patients than others. This finding should be 
examined in future research.   
Current practice for most treatment programs is to require all patients in treatment 
for OUD to attend counseling in order to stay in treatment. This requirement is 
potentially harmful in that it is not evidence based and may result in premature discharge 




(monetary, transportation, childcare) and a high number of touchpoints during care 
preclude some patients from attending counseling. This in turn presents a potentially 
harmful barrier and thus reduces access to treatment for those who need it.   
Additionally, clinicians should work actively to meet the needs of special 
populations in OUD treatment such as women, older adults, and patients with co-
occurring mental health disorders, chronic illnesses, and infectious diseases. Also, given 
the importance of treatment utilization, medication adherence, and treatment retention in 
preventing relapse of OUD, clinicians should actively work to improve retention in care 
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